February 2024

Curriculum Vitae and Publication List of

Prof. Dr. Dario Neri

Chief Executive Officer and Chief Scientific Officer of Philogen (www.philogen.com)

Professor, Department of Chemistry and Applied Biosciences, ETH Zürich (Switzerland)

Honorary Senior Visiting Fellow, Department of Radiology, University of Cambridge (U.K.)

Name Dario Neri (Swiss and Italian Nationality)

1) Life, Education and Appointments

Place and date of birth:	Rome (Italy), 1 May 1963
High School	1982, Maturita' Classica, Liceo E.S. Piccolomini, Siena (mark: 60/60)
Master Degree	1987, Chemistry ("Laurea di Dottore in Chimica"), both at the Scuola Normale Superiore and at the University of Pisa, Pisa, Italy (mark: 110/110 e lode) [supervisors: Prof.Dr. Renzo Rossi and Prof. Dr. Adriano Carpita]
Ph.D.	1992, Chemistry, Swiss Federal Institute of Technology Zurich (ETH Zürich), Switzerland (ETH Medal for the Dissertation) [supervisor: Prof. Dr. Kurt Wüthrich, Nobel Prize Chemistry 2002]
Postdoctoral Fellow	1992-1996, Cambridge Centre for Protein Engineering, Medical Research Council, Cambridge, UK [supervisor: Sir Gregory Winter, Nobel Prize Chemistry 2018]
Assistant Professor	1996-1999, Chair of Molecular Structural Biology, Department of Biology, Swiss Federal Institute of Technology (ETH Zürich), Switzerland
Associate Professor	1999-2002 , Chair of Biomacromolecules, Department of Applied BioSciences, Swiss Federal Institute of Technology (ETH Zürich), Switzerland
Full Professor	2002 - now , Chair of Biomacromolecules, Department of

	Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Switzerland
CEO and CSO	Oct 2020 – now, Philogen SpA [www.philogen.com]
Hon. Sen. Vis. Fellow	June 2022 - now, Department of Radiology, University of Cambridge (U.K.)

2) Awards

1992	Silver Medal of the ETH Zürich for the Ph.D. thesis (Chemistry)
1992-1995	EU Bridge Bursary for a post-doctoral Fellowship at the Cambridge Centre for Protein Engineering, MRC Centre, Cambridge (UK)
2000	Abbott Prize (with Luciano Zardi) of the International Society of Oncology and BioMarkers (ISOBM), Munich (Germany)
2000	2nd Prize, Biotec Award (with Adriano Aguzzi and Rosario Rizzuto), Milan (Italy)
2001	Mangia d'Oro, Siena (Italy)
2006	Prous Award for New Technologies in Drug Discovery, of the European Federation of Medicinal Chemistry, Istanbul (Turkey)
2007	Robert-Wenner-Prize of the Swiss Cancer League, Bern (Switzerland)
2008	SWISSBRIDGE Award, Zürich (Switzerland)
2011	Prix Mentzer of the French Society for Medicinal Chemistry, Lyon (France)
2014	Phoenix Award 2014 in Clinical Pharmacology, Vienna (Austria)
2015	ERC Advanced Grant
2019	ADC World Award, San Diego (U.S.A.)
2022	Paul Harris Fellow Award for Contributions to Science, Rome (Italy)

2023 Pratesi Medal of the Italian Chemical Society, Chieti (Italy)

3) Industrial activities

Dario Neri is the co-founder of Philogen (www.philogen.com), a Swiss-Italian Biotech group which has brought multiple antibody and molecule products into Phase I, Phase II and Phase III clinical trials, both in Europe and in the U.S.A.

Dario Neri and his colleagues led a successful Initial Public Offering (IPO) for Philogen on March 3rd 2021. Philogen is now listed on the Italian Stock Exchange (market cap at the time of IPO: 690 million €).

Former PhD students of Dario Neri have founded successful companies, including:

• Bicycle Therapeutics (www.bicycletherapeutics.com; Prof. Dr. Christian Heinis)

• Covagen (www.covagen.com; Dr. Julian Bertschinger and Dr. Dragan Grabulovski)

• Allcyte (www.allcyte.com; Dr. Nikolaus Krall)

• Atlyphe (www.atlyphe.com; Dr. Jonathan Kiefer)

4) Invited Lectures (since 2000)

2000

Engineering human antibodies that selectively target tumoural blood vessels
Tumor Targeting Symposium, Auditorium Maximum, ETH Zürich, Zürich, 25 February 2000

Engineering human antibodies that selectively target tumoural blood vessels
Department of Chemistry, EPF Lausanne, Lausanne, 8 March 2000

The use of phage display technology for the engineering of therapeutic proteins and novel enzymes
Main Lecture, Proteine 2000 (XV Meeting of the Workgroup on Structure and Function of Proteins of the Italian Society of Biochemistry and Molecular Biology), Varese (Italy), 17 April 2000.

Human antibodies that selectively target and ablate tumoural blood vessels
Invited Lecture, Max Planck Institut für Biophysik, Frankfurt (Germany), 10 May 2000.

Engineering recombinant antibodies for medical applications
Tebio (Mostra Convegno sulle Biotecnologie), Genova (Italy), 25 May 2000.

Engineering recombinant antibodies for medical applications
International Symposium "Peptide radiopharmaceuticals in diagnosis and therapy", Roma (Italy), 26 May 2000.

Ingegneria proteica di anticorpi terapeutici
Convegno "Gli anticorpi monoclonali 25 anni dopo", Istituto Superiore di Sanita', Roma (Italy), 29 May 2000.

Engineering anti-angiogenesis antibodies
XVIIth International Conference on "Advances in the Application of Monoclonal Antibodies in Clinical Oncology", Pythagorion, Samos (Greece), 2 June 2000.

Engineering recombinant antibodies for medical applications
Kantonsspital Basel, Neurochirurgie, 22 June 2000.

Immunoconjugates which selectively target and ablate neovasculature
„Hypoxia and its Role in Angiogenesis", Centro Stefano Franscini Workshop, Ascona, 29 June 2000.

Two-dimensional gel electrophoresis and antibody phage technology in angiogenesis research
4th Siena Meeting „From Genome to Proteome", Siena (Italy), 7 September 2000.

Engineering human antibodies that selectively target tumoural blood vessels
Abbott Award Lecture, XXVIII Meeting of the international society of oncodevelopmental biology and medicine "From tumor biology to clinical oncology", Munich (Germany), 10 September 2000.

Antibody-based targeting of angiogenesis,
Institute of Physiology, University Zürich, Zürich, 24 October 2000.

Human antibodies which selectively target and occlude tumoural blood vessels
Biotec Award 2000, Milano (Italy), 26 October 2000.

Engineering recombinant antibodies for medical applications
Entiwicklungsbiologie Seminar, ETHZ/UNIZH, Zürich, 7 November 2000.

Biological applications of infrared fluorescence imaging and microscopy
Workshop on „Infrared spectroscopy at the Swiss Light Source: methods and applications", Bern, 27 November 2000.

2001

Tumor Targeting
Externe Seminarwoche, Dept. Applied Biosciences ETH Zürich, Lenzerheide, 8 January 2001.

Proteomics and angiogenesis research
Trieste Proteomics Workshop, SISSA/ISAS, Trieste (Italy), 26 February 2001.

Antibody-based targeting of tumor angiogenesis
Swiss Institute for Cancer Research (ISREC), Epalinges, 12 March 2001

Biomedical applications of anti-angiogenesis antibodies
Rheumaklinik und Institut für Physikalische Medizin, University Hospital Zurich, Zurich, 16 March 2001

Proteomica, Angiogenesi e Nuovi Farmaci Anti-tumorali
Convegno „Quo vadis proteomics", Napoli (Itali), 26 March 2001.

Antibody-based targeting of angiogenesis
Meeting „Bioregio meets Bioropa", Heidelberg (Germany) 4 April 2001.

Immunoconjugates which specifically recognize and ablate the tumor vasculature
11th AEK Congress of the German Cancer Society, Heidelberg (Germany) 6 April 2001.

Antibody-based targeting of angiogenesis-related diseases
International School of Pharmacology's 63rd Course on „Angiogenesis and signal transduction in anti-cancer drug development:, Erice (Italy), 28 April 2001.

Immunoconjugates which specially recognise and ablate the tumour vasculature
The 18th International Conference on „Advances in the Application of Monoclonal Antibodies in Clinical Oncology", Vouliagmeni (Greece), 14 June 2001

Antibody-based targeting of angiogenesis-related diseases
Novartis Research Center, Basel, 3 July 2001.

Biomedical Technologies and Analytics

Journee de reflexion of the Swiss Academy of Engineering Sciences (SATW), Lausanne, 19 June 2001.

Generation of human monoclonal antibodies: phage display technology and beyond.
Symposium Recombinant Antibodies, Nestle' Research Center, Lausanne, 20 September 2001

Targeting tissue factor and the endothelium to inhibit angiogenesis
International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo (Italy), 2-4 November 2001.

The design of recombinant antibody molecules with optimal specificity and affinity for targeting tumor neovasculature
IBC's 12th International Conference on Antibody Engineering, San Diego (USA), 4 December 2001

2002

Antibody-based targeting of tumor neo-vasculature
25. Deutscher Krebskongress, ICC Berlin (Germany), 12 March 2002.

Imaging and therapy of cancer with antibody derivatives specific for the EDB domain of fibronectin, a marker of angiogenesis
Colloquium "Molecular approaches to cancer chemoprevention", German Cancer Research Center, Heidelberg (Germany) 15 March 2002.

Antibody-based targeting of angiogenesis
Antibodies 2002 Conference, Cancer Research Institute, New York (USA), 19 March 2002.

Robotic production of monoclonal antibodies
"Joining forces – New chemistry, informatics and Engineering-based approaches to study biological processes" - Interdisciplinary Mini-Symposium, Institute of Biochemistry, ETH Zürich (Switzerland), 22 March 2002.

Antibody-based targeting of angiogenesis
Center for Immunological Research, Schering-Plough, Dardilly (France), 2 April 2002.

Antibody Engineering
Ausbildungsmodul 8 (Produktion monoklonaler und polyklonaler Antikörper), Institut für Labortierkunde, Universität Zürich (Switzerland), 12 April 2002.

Challenges and opportunities in cancer therapy
PhD-Students Lecture Series, ETH Zürich (Switzerland), 15 April 2002.

Antibody-based targeting of tumor angiogenesis
2nd International "North Adriatic Sea" Symposium on novel targets for cancer therapy. Ravenna (Italy), 19 April 2002.

Antibody-based targeting of angiogenesis

International Center for Genetic Engineering and Biotechnology (CGEB), Trieste (Italy), 3 May 2002.

Tumor targeting
4th D-BIOL Symposium, ETH Zürich, Davos (Switrzerland), 8 May 2002.

Antibody-based targeting of angiogenesis
1st International Conference on Recombinant Antibodies, Berlin (Germany) 17 May 2002.

Antibody-based targeting of angiogenesis
Anatomical Institute, University of Zurich (Switzerland), 22 May 2002.

Antibody-based targeting of angiogenesis
Angiogenesis: basic mechanisms and therapeutic implications. Monte Verita' by Ascona, Switzerland, June 2-7 2002.

EDB domain of fibronectin
1st International Conference on Vascular Targeting, Boston (USA), 13 June 2002.

Tumor targeting: antibody fragments and beyond
The 19th International Conference on „Advances in the Application of Monoclonal Antibodies in Clinical Oncology", Vouliagmeni (Greece), 26-28 June 2002

Antibody-based targeting of angiogenesis
XXXth Meeting of the International Society for Oncodevelopmental Biology and Medicine, Boston (USA), 8-12 September 2002.

Antibody-based targeting of angiogenesis
2nd International Meeting „Angiogenesis", Kloster Seeon (Germany) 21-24 September 2002.

Antibody-based targeting of angiogenesis
European School of Haematology
Cascais (Portugal) 12-15 October 2002.

Antibody-based targeting of angiogenesis
Opening Symposium of the FLUOR-MMPI European Union Project, Milano (Italy) 25 October 2002.

Antibody-based targeting of angiogenesis
Symposium „Understanding the Structural Basis of Molecular Interaction", Charite', Berlin (Germany), 7 December 2002.

Tumor targeting: antibody fragments and beyond

IBC's 12th International Conference on Antibody Engineering, San Diego (USA), 1-5 December 2002

2003

Tumor Targeting
Symposium in the Honour of 5 Retiring Professors, Institute of Biochemistry, University of Lausanne, 20 January 2003.

Antibody-based targeting of angiogenesis
Antibody-based therapeutics for cancer, Keystone Symposia, Banff (Canada) 4-9 February 2003.

Antibody-based targeting of angiogenesis
2nd International Meeting on Angiogenesis, Leiden (The Netherlands), 13-15 February 2003

Vascular Targeting
Symposium on Vector Targeting Strategies for Gene Therapy, Cold Spring Harbor, NY (USA) 20-23 March 2003

Angiogenesis: molecular imaging
Schering Symposium "MRI: from current knowledge to new horizons", Berlin (Germany) 28-29 March 2003

Libraries of antibodies, of single domain binders and of encoded self-assembling chemical compounds: a comparison
2nd International Congress on Recombinant Antibodies, Munich (Germany) 29-30 April 2003.

Tumor targeting with antibodies to the EDB domain of fibronectin
Angiogenesis 2 Euroconferences, Institut Pasteur, Paris (France) 19-20 June 2003

In vivo proteomics: from target identification to new drugs.
"Proteomics and the proteome", 6th Annual IBC Conference, Basel (Switzerland) 30June-2 July 2003

Antibody-based targeting of angiogenesis.
31st Meeting of the International Society for Oncodevelopmental Biology and Medicine, Edinburgh (UK), 30 August – 4 September 2003.

Targeting the vascular endothelium: novel approaches
Second International Conference on Thrombosis and hemostasis Issues in Cancer. Bergamo (Italy) 19-21 September 2003.

Vascular tumor targeting
3rd Interdisciplinary Euroconference on Angiogenesis, European School of Haematology, Saggart Co. Dublin (Ireland) 24-27 October 2003.

2004

Ligand-based targeting of neo-vasculature
Second International Conference on Vascular Targeting
Wyndham Miami Beach Resort, Miami (Florida, USA) 16-18 May 2004

Vascular targeting: from target identification to clinical trials
Fourth Interdisciplinary Euroconference on Angiogenesis, European School of Haematology, Helsinki (Finland) 21-24 May 2004.

Ligand-based targeting of angiogenesis: from the bench to the clinic
Department of Chemistry and Biochemistry, University of California Los Angeles, 2 June 2004

In vivo biotinylation for the discovery of vascular markers of pathology.
6th Siena Meeting „From Genome to Proteome“, Siena (Italy), 30 August - 2 September 2004.

Antibody-based targeting of tumor angiogenesis
Istituto Oncologico della Svizzera Italiana, Bellinzona (Switzerland), 14 September 2004

Ligand-based targeting of tumor angiogenesis: from the bench to the clinic.
“Heterologous gene expression in mammalian cells”. Third European BioTechnology Workshop, Kartause Ittingen (Switzerland), 19-21 September 2004.

Antibody therapies targeting the stromal compartment
16th EORTC-NCI-AACR symposium on “Molecular Targets and Cancer Therapeutics”
Geneva (Switzerland) 28 September-1 October 2004.

Targeting the tumor vasculature with antibody-TNF and other fusion proteins
10th International TNF Superfamily Conference
Lausanne (Switzerland) 29 September – 2 October

Immunophotodetection and immunophototherapy of angiogenesis-related diseases
15th International IBC Conference on Antibody Engineering
San Diego (California, USA) 30 November – 3 December 2004

2005

Antibody-promoted tumor blood vessels thrombosis
Keystone Symposium on Antibody-based therapeutics for cancer
Santa Fe (New Mexico, USA) 17-22 February 2005

Vascular targeting: from the bench to the clinic
Lecture at the Pharma-Day, Pharma Center Basel – Zurich, University of Basel, 11 March 2005

Molecular Targeting of Angiogenesis
Appuntamenti con la Biologia – Seminari di Ricerca
ENEA (Ente per le Nuove Tecnologie, Energia e Ambiente), Centro Ricerche Casaccia, Roma (Italy) 23 March 2005.

Ligand-based targeting of pathological angiogenesis
Lecture at Novartis, Basel 12 April 2005

Round-Table “Il contributo delle aziende italiane alla messa a punto di nuovi farmaci biotecnologici: dalla discovery allo sviluppo clinico”
BIONOVA, Padova (Italy) 21 April 2005

Targeting specific vascular beds
First Annual Conference of the ARVO/Pfizer Ophthalmics Research Institute
“Angiogenesis, Neovascularization and Vasoproliferation”
Fort Lauderdale (Florida, USA) 28-30 April 2005

High–affinity protein binders from antibody libraries and from encoded chemical libraries
Lecture at the European Molecular Biology Laboratory (EMBL), Heidelberg (Germany) 2 May 2005

Vascular Tumor Targeting
Lecture at the Deutsches Krebsforschungszentrum (DKFZ) Heidelberg (Germany) 2 May 2005

Vascular Targeting
Lecture at the Rudbeck Laboratory, Dept. of Genetics and Pathology, University of Uppsala (Sweden) 12 May 2005

Targeting of antibodies: different strategies in development
Plenary Lecture at the 4th International Conference on Recombinant Antibodies, Berlin (Germany) 31 May – 3 June 2005

Tumor Targeting
4. Biotechnologie-Tag and der Universität Leipzig, Leipzig (Germany) 3 June 2005

Vascular Targeting and Proteomic Research
Summer School - Functional Genomics in Cardiovascular Medicine, Greifswald (Germany) 25 August 2005

Radioimmunotherapy of angiogenesis-related diseases
Mini-Symposium “Targeted Radionuclide Therapy”, Paul-Scherrer-Institut, Villigen, 3 September 2005

Ligand-based vascular tumor targeting
Lecture at the Meeting of the Roche Center for Functional Genomics, Buonas (Switzerland) 6 September 2005

Vascular Tumor Targeting
VIII Congresso Nazionale di Biotecnologie, Siena (Italy) 7-9 September 2005

Ligand-based targeting of angiogenesis; from the bench to the clinic
2nd International Conference in Monte Verita’ “Tumor-host interaction and angiogenesis: basic mechanisms and therapeutic perspectives” – Ascona 1-5 October 2005

Vascular Targeting
Lecture at the Biomedicum Helsinki Seminar Series, Helsinki (Finland) 17 October 2005

Vascular Tumor Targeting
Lecture at the Department of Pathology of the University of Liege, Liege (Belgium) 28 October 2005

Vascular Tumor Targeting
Lecture at the Center for Clinical Research, University Hospital Zurich, Zurich (Switzerland) 4 November 2005

Vascular Tumor Targeting
One-Day International Symposium Canceropole PACA "Signalling pathways in cancer and targeted treatments", Centre Antoine Lacassagne, Nice (France) 5 November 2005

Antibody-Cytokine Fusion Proteins as Novel Anti-Cancer Therapeutics
"Next-Generation Protein Therapeutics" IBC Conference, Basel (Switzerland) 7-10 November 2005

Vascular Tumor Targeting
Workshop "Monoclonal antibodies: research, development andapplications", Istituto Superiore di Sanita', Rome (Italy) 22-23 November 2005

Encoded self-assembling chemical libraries
Lecture at Bayer, Monnheim (Germany), 9 December 2005

Vascular tumor targeting
Lecture at the Institut für Klinische Pharmakologie, University of Bern (Switzerland) 21 December 2005.

2006

Vascular tumor targeting
10th Swiss Receptor Workshop, Basel (Switzerland) 12-15 March 2006

Vascular tumor targeting
Lecture at the Institute of Clinical Pathology of the University of Zurich (Switzerland), 10 April 2006

Vascular antigen discovery by in vivo and ex vivo biotinylation and antibody phage technology
Keynote Lecture at the Protein Engineering Summit, Boston (USA), 24-28 April 2006

Ligand-based vascular targeting
Lecture at the Department of Chemistry and Biochemistry of the University of Bern (Switzerland), 2 May 2006

Herstellung therapeutischer Proteine
Biotech-Forum: Vom Gen zum Protein, Advanced studies "Kurs Spitalpharmazie", Bern (Switzerland) 11 May 2006

Vascular tumor targeting

41st Congress of the European Society for Surgical Research, Rostock (Germany) 17-20 May 2006

Chemical proteomics and vascular tumor targeting
Lecture at the Department of Structural Biology and Bioinformatics, University Hospital of Geneva (Switzerland), 13 June 2006

Antibody phage technology
Modul VIII training Course of the Institut für Labortierkunde of the University of Zurich (Switzerland), 21 June 2006

Chemical proteomics and antibody phage technology for the discovery of novel tumor vascular antigens
IBC Recombinant Antibodies Conference, Zurich (Switzerland) 27-29 June 2006

Tumor vascular targeting
18th Pezcoller Symposium "Tumor microenvironment: heterotypic interactions", Trento (Italy) 27-29 June 2006

Chemical Proteomics and vascular tumor targeting
Keynote opening lecture at the 1st Annual Congress of the Italian Proteomic Association, Pisa (Italy) 2-4 July 2006

Vascular targeting in cancer and chronic inflammation: from the bench to the clinic
Lecture at Novartis Basel (Switzerland), 13 July 2006

Vascular tumor targeting: from the bench to the clinic
Biochemical Society Focused Meeting "Cellular delivery of therapeutic macromolecules". Cardiff (UK), 30 August 2006.

Vascular tumor targeting: from the bench to the clinic
19th International Meeting on Medicinal Chemistry, Istanbul (Turkey), 1 September 2006

Discovery of vascular tumor markers using chemical proteomic methodologies.
7th Siena Meeting "From genome to proteome". Siena (Italy), 7 September 2006.

Vascular tumor targeting
Xth Melanoma Conference, Nordwijk (The Netherlands), 15 September 2006

Vascular tumor targeting: from the bench to the clinic
Prous Science Symposium, Barcelona (Spain), 18 September 2006

Targets, targeting and proteomics
7th Swiss Course on Medicinal Chemistry, Leysin (Switzerland), 1-6 October 2006

Vascular tumor targeting: from the bench to the clinic
EU Workshop "Molecular targets for cancer programme", Luxembourg, 6-7 October 2006

Vascular tumor targeting

Lecture at the University of Padova (Italy), 10 October 2006.

Antibody-based vascular tumor targeting: from target discovery to clinical trials
HUPO 5th Annual World Congress, Long Beach (USA) 28 October – 1 November 2006

Vascular targeting
18th EORTC-NCI-AACR Symposium, Prague (Czech Republic) 7-10 November 2006.

Ligand-based targeted therapies
Symposium "Milano new drugs, angiogenesis, environment and stroma: models, research and care". Milano (Italy), 10-11 November 2006

2007

Antibody Targeting of the extracellular matrix
Lecture at the Biozentrum of the University of Basel (Switzerland), 17 January 2007-09-13

Vascular Targeting with Recombinant Antibody Derivatives
Keystone Symposium on Antibodies as Therapeutics, Lake Louise (Canada), 1-5 February 2007

Vascular targeting: target identification, ligand isolation and clinical development of therapeutics
VI Laboratorio di Metodologie Sintetiche in Chimica Farmaceutica. Siena (Italy) 11-16 February 2007.

Vascular tumor targeting
IFOM-IEOcampus FRIDAYSEMMinars, Milano (Italy) 23 March 2007.

Engineering antibody-based fusion proteins for therapeutic applications
2nd Singapore Biologics Manufacturing Conference (Singapore) 28-30 March 2007

Ligand-based vascular tumor targeting: from the bench to the clinic
Seminars of the MRC Human Genetics Unit, Edinburgh (UK), 12 April 2007

Antibody-based vascular tumor targeting: from the bench to the clinic
Cancer Immunotherapy CIMT Meeting, Würzburg (Germany), 13 April 2007

Vascular tumor targeting
Seminar at the University of Catania (Italy), 23 April 2007.

Antibody-based vascular tumor targeting
The Protein Engineering Summit (PEGS), Boston (USA), 14-18 May 2007

Vascular tumor targeting
Seminar at the Institute of Clinical Chemistry, University of Zurich (Switzerland) 22 May 2007.

Vascular tumor targeting
"The Future of Medical Sciences", Milano (Italy) 7 June 2007.

Antibody-based vascular tumor targeting
Recombinant Antibodies IBC Conference, Berlin (Germany) 31 May – 3 June 2007

Vascular tumor targeting: about targets, ligands and applications
CCA/V-ICI Keynote Lecture. VUMC Cancer Center Amsterdam (The Netherlands) 10 September 2007

Vascular targeting antibody derivatives: from bench to the clinic
Lecture at the International Meeting "Cellular and Molecular Mechanisms of Tumor Progression and Metastasis", Kloster Seeon (Germany) 22-25 September 2007

Vascular targeting of cancer and of chronic inflammation
International Conference on "Vascular Targeted Therapies in Oncology", Mandelieu (France) 4-8 October 2007

Antibody-Based Vascular Targeting: From The Bench To The Clinic
49° Congresso Nazionale della Societa' Italiana di Cancerologia. Pordenone (Italy) 26-29 November 2007

2008

Vascular tumor targeting: from the bench to the clinic
Lecture at the University Hospital, Basel (Switzerland) 20 February 2008

Targeting the tumor vasculature: from the bench to the clinic
Lecture at the Friedrich Miescher Institute, Basel (Switzerland) 4 March 2008

Panel Discussant on Anti-Angiogenic Therapy of Neuroendocrine Tumors
ENETS Congress, Paris (France), 8 March 2008

Vascular Tumor Targeting: from the bench to the clinic
Lecture at the Scuola Normale Superiore, Pisa (Italy) 14 March 2008

Next generation antibody therapeutics
Symposium "Biopharmaceuticals - Technologien für neue Therapeutika", Benediktbeuern (Germany) 15 April 2008

Vascular tumor targeting: from the bench to the clinic
Seminar at Nerviano Medical Sciences, Nerviano (Italy) 9 May 2008

Chemical proteomics for the discovery of vascular markers of disease
Lecture at the 3rd Annual Biomarkers Congress, Manchester (UK) 15 May 2008

Antibody-based vascular tumor targeting
Lecture at the Minisymposium "Drug Targeting" of the Division for Medicinal Chemistry of the Swiss Chemical Society, Basel (Switzerland), 29 May 2008

The use of blood vessels as targets

7th International Conference on Recombinant Antibodies, Dublin (Ireland) 24-26 June, 2008

Vascular targeting antibodies: from the bench to the clinic
20th Meeting of the European Association for Cancer Research, Lyon (France) 5-8 July, 2008

Tumor targeting
Lecture at the Exploratory Worskshop "Molecular signaling in cardiovascular and oncological diseases: similar and shared pathways" of the European Science Foundation. Pisa (Italy) 15 July 2008

Antibody-based vascular targeting: from the bench to the clinic
Lecture at the Departement Klinische Forschung, University of Bern (Switzerland), 1 September 2008

DNA-encoded chemical libraries
Lecture at Novartis, Basel (Switzerland) 8 September 2008.

Antibody-based vascular tumor targeting: from the bench to the clinic
Lecture at the Collegium Helveticum, Forum Medizinische Wissenschaften “Onkologie”, Zurich (Switzerland) 24 September 2008

Antibody-based vascular tumor targeting: from the bench to the clinic
Lecture at the Department of Dermatology, University of Zurich (Switzerland) 24 September 2008

DNA-encoded chemical libraries
Lecture at MipTec, Basel (Switzerland) 14-16 October 2008

Vascular targeting antibodies for the therapy of cancer and arthritis: from the bench to the clinic
International Symposium "Recombinant Antibodies: new developments for future challenges
CNIO, Madrid (Spain), 22 October 2008

Vascular targeting antibodies for the therapy of cancer and arthritis: from the bench to the clinic
Lecture at the Symposium “Protein Engineering and the Design of new Therapeutic Proteins”. Emeryville (USA), 6 November 2008.

Engineering of antibody-based therapeutics and imaging agents: from the bench to the clinic
Lecture at the Biotechnet Switzerland / Swiss Biotech Association Meeting, Olten (Switzerland) 19 November 2008

Vascular targeting with recombinant antibody derivatives
Lecture at the 19th International IBC Conference on Antibody Engineering, San Diego (USA), 8 December 2008.

2009

Next-generation therapeutic antibodies
VIth Symposium of the Austrian Proteomics Platform, Seefeld (Austria) 18-21 January 2009

Vascular targeting antibodies for the therapy of cancer and arthritis: from the bench to the clinic
Lecture at the Center for Molecular Medicine (CeMM), Vienna (Austria) 11 May 2009

Vascular targeting in melanoma
7th World Congress on Melanoma/5th Congress of the European Association of Dermato-Oncology (EADO), Vienna (Austria) 13 May 2009

Vascular tumor targeting: from the bench to the clinic
Lecture at the BIOTEC.ORG meeting of the Societa' Chimica Italiana, Forte dei Marmi, Lucca (Italy) 21 May 2009

Antibody-based vascular tumor targeting: from the bench to the clinic
Keynote Lecture at the "Targeting alpha-particle emitting radionuclides to combat cancer" (TARCC) Meeting, Nantes (France) 26 May 2009.

Vascular tumor targeting: from the bench to the clinic
Lecture at the University College Dublin, Dublin (Ireland), 6 June 2009

Vascular targeting antibody derivatives: from the bench to the clinic
IBC Recombinant Antibodies Conference, Köln (Germany), 18 June 2009

Chemical proteomics for the discovery of vascular markers of pathology: from the bench to the clinic.
4th Annual National ItPA Conference, Milano (Italy) 25 June 2009

Antibody-based vascular targeting: from the bench to the clinic.
3rd European Conference on Chemistry for Life Sciences (ECCLS), Frankfurt am Main (Germany) 4 September 2009

Vascular targeting antibody-photosensitizer conjugates for the therapy of cancer and other angiogenesis-related diseases
European Society of Photobiology, Wroclaw (Poland) 7 September 2009

Ligand-based vascular targeting: from the bench to the clinic
Switzerland-Japan Biomolecular Chemistry Symposium, Tokyo (Japan) 12 September 2009

Translating proteomics to the clinic
Lecture at the HUPO Congress, Toronto (Canada) 27 September 2009

Vascular tumor targeting: from the bench to the clinic
Keynote lecture at the ISOBM Conference, Amsterdam (The Netherlands), 29 September 2009

Vascular tumor targeting: from the bench to the clinic
PEGS Europe: Protein Engineering Summit. Hannover (Germany) 6-8 October 2009

Vascular targeting antibodies in cancer and arthritis: from the bench to the clinic.
MipTec, Basel (Switzerland) 13-15 October 2009.

Über die nächste Generation von Medikamenten
Life Sciences Dialogue, Heidelberg (Germany) 22 October 2009.

Technology Transfer: breaking the barriers for improving academia to industry collaboration
Round Table at Chem Med 2009, Milano (Italy) 27 November 2009.

DNA-encoded chemical libraries
6th Status Seminar Chemical Biology 2009, DECHEMA, Frankfurt am Main (Germany) 30 November 2009.

Vascular tumor targeting: from target discovery to clinical applications
Swiss Proteomic Society Meeting, Zurich (Switzerland) 2-4 December 2009.

Antikörper in der Krebstherapie
Lecture at the Pharmazeutische Gesellschaft Zürich, Zurich (Switzerland) 10 December 2009.

2010

Vascular targeting
Lecture at Sanofi-Aventis, Frankfurt (Germany) 14 January 2010

Chemical proteomics for the discovery of vascular targets of disease
Lecture at MedImmune, Cambrdige (UK) 3 February 2010.

Antibody-based vascular targeting
Lecture at Kudos Pharmaceuticals, Cambridge (UK) 4 February 2010

Angiogenesis: where are we now?
7th Annual ENETS Conference, Berlin (Germany) 11 March 2010.

Identification of disease-specific marker molecules
DFG-Excellence Academy Molecular Imaging, Aachen (Germany) 27 April 2010

Curing cancer with vascular targeting antibody derivatives
Lecture at the University of Milano (Italy), 30 April 2010

Overview on molecular ligand- and target-systems in cancer
3rd European Conference for Clinical Nanomedicine, Basel (Switzerland), 11 May 2010

Antibody-drug conjugates targeting the tumor neo-vasculature
6th Annual PEGS Conference, Boston (USA), 16 May 2010.

Vascular targeting antibody derivatives for the therapy of cancer and
arthritis: from the bench to the clinic
IBC Conference on Recombinant Antibodies, Berlin (Germany), 17 June 2010

Vascular tumor targeting antibodies: from the bench to the clinic

2. Symposium “Tumor microenvironment: Bedeutung für Tumorbiologie und Kinik”, UniversitätsTumorCentrum Jena (Germany), 18 June 2010

Vascular Tumor Targeting
Opening Lecture at the 46th International Conference on Medicinal Chemistry (RICT), Reims (France), 30 June 2010

Vascular Tumor Targeting
Lecture for the DFG Sonderforschungbereich “Control of cell motility in morphogenesis, cancer invasion and metastasis”, Freiburg (Germany), 9 July 2010

Vascular Tumor Targeting
Lecture at the Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (I.R.S.T.), Meldola (Italy), 13 July 2010.

Opening Remarks
2nd International Conference on DNA-Encoded Chemical Libraries, Zurich (Switzerland), 20 August 2010.

Curing cancer with antibody derivatives.
CIBB Frontiers in Cancer Biology Lecture at Pfizer, Pearl River NY (USA), 25 August 2010.

Phage Antibodies for Vascular Targeting
Therapeutic Antibodies and Beyond: Celebrating 20 Years of Display Technologies. St. John’s College, Cambridge (UK), 7 September 2010.

Vascular tumor targeting
Three Decades of Protein Engineering: Impact on Structural Biology and Therapy. Department of Chemistry, University of Cambridge (UK) 23-24 September.

Vascular targeting with antibody derivatives: from the bench to the clinic.
Lecture at Maastro Clinic, Maastricht (The Netherlands), 14 October 2010.

Curing cancer with antibody derivatives
Keynote Lecture at the “Giornata del Dipartimento”, Universita’ di Milano Bicocca (Italy), 22 October 2010.

Curing cancer with vascular targeting antibody derivatives
Keynote lecture at the Congress “Tumor-Host Interaction and Angiogenesis: Mechanisms and Therapeutic Implication”. Ascona (Switzerland), 3 November 2010

Targeting antigens with antibody derivatives for imaging and therapy
Optical Imaging Workshop at the Max-Planck-Institute for Experimental Medicine. Göttingen (Germany) 25 November 2010.

Engineering Antibody pharmacokinetics by chemical modification and by gene fusion: preclinical and clinical results. I
IBC’s 21st International Conference on Antibody Engineering. San Diego (San Diego). 8 December 2010

2011

Vascular tumor targeting.
Plenary lecture at the 16th AEK International Cancer Congress, Düsseldorf (Germany) 18 March 2011.

Vascular tumor targeting
Lecture at NovImmune, Geneva (Switzerland), 8 April 2011.

Armed antibodies targeting the tumor neo-vasculature
Informa 10th Recombinant Antibodies Conference, Barcelona (Spain), 26 May 2011

Vascular tumor targeting: from the bench to the clinic.
Lecture at the Center for Integrative Science, University of Chicago (USA), 3 June 2011.

Vascular targeting antibody derivatives: results from Phase II clinical trials.
8th International Symposium on the Biology of Endothelial Cells, Zurich (Switzerland) 18 June 2011.

Vascular tumor targeting: from target discovery to clinical trials
EMBO Cancer Proteomics Conference, Dublin (Ireland), 23 June 2011

DNA-Encoded chemical libraries: a new tool for drug discovery.
Mentzer Award Lecture, 46th Conference of the French Society for Medicinal Chemistry, Lyon (France), 8 July 2011.

Vascular tumor targeting: from target identification to clinical trials
Lecture at the HUPO Congress, Geneva (Switzerland), 7 September 2011

Vascular tumor targeting: basic research and results from clinical trials.
International Symposium "The tumor – vessel interface". Kloster Seeon (Germany), 19 September 2011

DNA-encoded chemical libraries
Lecture at Novartis, Basel (Switzerland), 22 September 2011

From bench to clinic: experiences with cytokine-antibody fusion proteins.
Keynote Lecture at PEGS Europe, Hannover (Germany) 13 October 2011

Considerations on the role of ETH in Biotech and Pharma.
Dialogue ETH-Industry, Lausanne (Switzerland), 28 October 2011

Vascular tumor targeting: from the bench to the clinic
Lecture at the LMU University, Munich (Germany), 3 November 2011

Targeting the extracellular matrix of angiogenic vasculature

IBC's 9th Annual International Conference on Antibody Therapeutics, San Diego (USA), 4-8 December 2011.

2012

Vascular targeting: from the bench to the clinic
Lecture at the Walter-Brendel-Centre of Experimental Medicine, LMU University, Munich (Germany), 2 February 2012.

Drug Discovery in Academia: Challenges and Success Stories, with a Focus on Biotech Drugs
USGEB 2012 "When Biology meets Chemistry", Lausanne (Switzerland), 7 February 2012

Targeting the tumor extracellular matrix with armed antibodies
"Tumor extracellular matrix: an emerging target for therapies". Major Symposium at the AACR Annual Meeting, Chicago (U.S.A.), 3 April 2012.

New CAIX ligands from DNA-encoded chemical libraries: isolation and pharmaceutical applications
The 9th International Conference on Carbonic Anhydrase, Antalya (Turkey), 13 April 2012.

Monoclonal antibody small immunoprotein (SIP) tumor targeting in patients with cancer
2nd International Conference "Translational Research in Oncology: a New Approach to Personalized Medicine", Forli' (Italy), 9 May 2012

DNA-encoded chemical libraries: new tools for drug discovery
Lecture at the Institut de Recerca Biomedica, Barcelona (Spain), 10 May 2012

Armed antibodies and targeted cytotoxics: from the bench to the clinic
IV EWDSy – Fourth European Workshop in Drug Synthesis, Siena (Italy), 28 May 2012

Vascular targeting with armed antibodies: from the bench to the clinic
17th International Vascular Biology Meeting, Wiesbaden (Germany), 3 June 2012

Targeting the angiogenic extracellular matrix with armed antibodies
"Tumor microenvironment: Bedeutung für Tumorbiologie und Klinik," Universitäts Tumor Centrum, Jena (Germany, 8 June 2012

Angiogenesis: close to prescription
Lecture at the EULAR Congress, Berlin (Germany) 9 June 2012.

Teleukin (F16-IL2)
Lecture at the Kick-Off meeting of the FP7 EU Project "Immomec", Graz (Austria), 11 June

A critical comparison of drugs and other payloads fr the development of armed antibodies.
Antibody Drug Conjugates, Informa Recombinant Antibodies Conference, Berlin (Germany), 13-14 June

Immunocytokines: a class of potent armed antibodies.

Antibody Drug Conjugates, Informa Recombinant Antibodies Conference, Berlin (Germany), 13-14 June

Armed antibodies for the therapy of cancer and of RA.
Keynote Lecture at the Next-Generation Protein Therapeutics Summit, San Francisco (USA), 25-27 June

Vascular Targeting: from the bench to the clinic.
Lecture at the University of Texas Southwestern, Dallas (USA), 27 June

Vascular Targeting: from the bench to the clinic.
Lecture at Merrimack Pharmaceuticals, Cambridge (USA), 28 June

DNA-Encoded Chemical Libraries: a tool for drug discovery
3rd European Chemical Biology Symposium, Vienna (Austria), 1-3 July

Targeted cytotoxics from DNA-encoded chemical libraries.
3rd International Symposium on DNA-Encoded Chemical Libraries, Zurich (Switzerland), 20 August 2012

Vascular Targeting: from the bench to the clinic.
Swiss Pharma Science Day 2012, Bern (Switzerland), 29 August

Arming antibodies with drugs and other payloads: from the bench to the clinic.
Lecture at the European Federation for Medicinal Chemistry Congress, Berlin (Germany), 3 September 2012.

Vascular Targeting: from the bench to the clinic
Lecture at the Institute of Chemistry and Biochemistry, Freie Universität Berlin (Germany) 5 November 2012

What can we learn from preclinical mouse experiments for clinical development of antibody drugs?
Keynote Lecture at the 6th World Meeting of Interndisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress, Barcelona (Spain) 16 November 2012

Vascular Targeting: from the bench to the clinic
Lecture at the Fondazione Pascale, Napoli (Italy) 20 November 2012

Armed antibodies: a critical comparison of different payloads
European Antibody Congress 2012, Geneva (Switzerland) 27-28 November 2012

DNA-encoded chemical libraries as tools for drug discovery
Delivering immune modulators at the sites of disease
IBC's 23th Annual International Conference on Antibody Engineering, San Diego (U.S.A.), 2-6 December 2012

Delivering immune modulators to the sub-endothelial extracellular matrix at the sites of disease

Keynote Lecture at the IBC's 10th Annual Antibody Therapeutics, San Diego (U.S.A.), 2-6 December 2012

2013

Vascular targeting with armed antibodies: from the bench to the clinic.
Lecture at the Department of Hematology, Christian-Albrechts-University, Kiel (Germany), 24 January 2013

Antibody based targeting agents for imaging and therapy
Keystone Symposia "Antibodies as Drugs" (J3, 2013) and "Cancer Immunology and Immunotherapy" (J4, 2013), Vancouver (Canada), 27 January – 1 February 2013

Targeting cancer with armed antibodies
Lecture at the Department of Hematology, University Hospital of Münster (Germany), 5 March 2013

From proteomic target discovery to clinical studies with armed antibodies
Proteomic Forum Berlin 2013, Berlin (Germany), 19 March 2013

Arming antibodies with cytokines, radionuclides and drugs: a comparative evaluation
6th Annual Proteins Congress, Novotel London West, London (UK) 25-26 March 2013

Tumor targeting: from armed antibodies to small targeted cytotoxics
Chemical Protein Synthesis Meeting, Department of Chemistry, University of Vienna (Austria), 3-6 April 2013

La Biotecnologia. Che cosa e'? A cosa serve? Ha un ruolo da giocare per Siena?
"Siena verso il futuro. Un viaggio nell'economia senese: le biotecnologie". Ordine dei Commercialisti e degli esperti contabili di Siena, Siena (Italy), 12 April 2013

Antibody-cytokine fusions (immunocytokines): from the bench to the clinic
Informa Life Sciences' Empowered Antibodies Congress, Barcelona (Spain), 12-13 June 2013

Targeting non-oncological applications with armed antibodies
Informa Life Sciences' Empowered Antibodies Congress, Barcelona (Spain), 12-13 June 2013

Arming antibodies with drugs, radionuclides and cytokines: preclinical and clinical experience
"Vectorization of bioactive molecules". 20ème Journée de Chimie Pierre Fabre, Castres (France) 13 June 2013

Targeting the tumor stroma with armed antibodies
Opening Lecture at the Beatson International Cancer Conference "Targeting the tumour stroma". Glasgow (UK), 7-10 July 2013

Armed antibodies and targeted cytotoxics: from the bench to the clinic
Keynote Lecture at the XXII National Meeting on Medicinal Chemistry, Roma (Italy) 10-13 September 2013

Chemical proteomics for target identification and for the development of therapeutic antibodies: from the bench to the clinic
HUPO Congress, Yokohama (Japan), 14-18 September 2013

How I became an academic biotech entrepreneur
Lecture at INSEAD, FOCIS Entrepreneurs in Clinical Academia, Fontainebelau (France), September 23-27 2013

Von NMR Untersuchungen an Proteinen zu klinischen Studien mit therapeutischen Antikörpern
Symposium anlässlich des 75. Geburtstags von Kurt Wüthrich, Zürich (Switzerland), 9 October 2013.

Biologics and biosimilars: focus on armed antibodies
23rd Solvay Conference in Chemistry "New Chemistry and New Opportunities from the Expanding Protein Universe", Brussels (Belgium), 16-19 October 2013

DNA-encoded chemical libraries: a new tool for drug discovery
Lecture at the Department of Chemistry, University of Basel (Switzerland), 15 November 2013.

DNA-encoded chemical libraries: a new tool for drug discovery
Lecture at the Department of Chemistry, Peking University, Beijing (China), 20 November 2013.

Innovative chemistry for vascular targeting applications: from the bench to the clinic.
Lecture at the Department of Chemistry, Peking University, Beijing (China), 21 November 2013.

Curing cancer with armed antibodies and small targeted cytotoxics
Xingda Lecture, Peking University, Beijing (China), 22 November 2013.

Targeting angiogenesis with armed antibodies
Lecture at the Center of Experimental Rheumatology, University Hospital Zürich, (Switzerland), 26 November 2013.

Monoclonal antibodies and their potential in CVD treatment.
Amgen Hyperlipidemia Academy, Berlin (Germany), 7 December 2013.

2014

Vascular targeting in cancer and in chronic inflammation: from the bench to the clinic.
Lecture at the Institute of Molecular Medicine, Lisbon (Portugal), 27 January 2014.

Armed antibodies for the therapy of cancer and of chronic information: from the bench to the clinic.
Keynote lecture at HI-STEM 5-year Anniversary Symposium, German Cancer Research Center, Heidelberg (Germany), 26 March 2014.

A critical evaluation of the disease-homing properties of bifunctional antibody products
PEGS Conference, Boston (USA), 8 May 2014

Targeting splice isoforms of tenascin-C with armed antibodies: from the bench to the clinic
Spring Symposium “Tenascins: defining their role in homeostasis and cancer”. Strasbourg (France), 13 May 2014

Vascular targeting for the therapy of cancer and of chronic inflammation: from the bench to the clinic
Lecture at the Italian Institute of Technology, Genova (Italy), 16 May 2014

Armed antibodies for the therapy of cancer and of chronic inflammation: from the bench to the clinic
Keynote Lecture, Istituto “Giannina Gaslini”, Genova (Italy), 16 May 2014.

Armed antibodies for the therapy of cancer and of chronic inflammation: from the bench to the clinic
Seminar Series on Advances in Immunotherapy. Genmab and University of Utrecht, Utrecht (The Netherlands), 27 May 2014

Targeted cytotoxics for cancer therapy
“Antibody-Drug Conjugates” Symposium at Carbogen, Bubendorf (Switzerland), 4 June 2014

Antibodies for cancer therapy
Scuola di Dottorato in Chimica e Chimica Industriale, Universita’ Statale, Milano (Italy), 5 June 2014

Drug conjugates for cancer therapy
Scuola di Dottorato in Chimica e Chimica Industriale, Universita’ Statale, Milano (Italy), 6 June 2014

Targeting cancer with armed antibodies and small targeted cytotoxics: from the bench to the clinic
Seminar Series at GIRG, Grenoble (France), 10 June 2014

Monoclonal antibodies and their potential in CVD treatment
AMGEN Symposium at the Schweizerische Gesellschaft für Kardiologie, Interlaken (Switzerland), 12 June 2014

Monoclonal antibodies
AIFA Course on Monoclonal Antibodies, Roma (Italy), 30 June 2014

Targeting the extracellular matrix with armed antibodies for the therapy of cancer and of chronic inflammation
Lecture at the Novo-Nordisk Research Center, Copenhagen (Denmark), 29 August 2014

Targeting tumors with armed antibodies and small targeted cytotoxics
Keynote Lecture at ELRIG 2014 Conference, Manchester (UK), 3 September 2014

Immunocytokines for the therapy of solid tumours and of haematological malignancies
Lecture at the University of Southampton, Cancer Sciences Unit, Southampton (UK), 10 September 2014.

Novel tumor targeting agents from DNA-encoded chemical libraries
Lecture at the FBLD 2014 Conference, Basel (Switzerland), 23 September 2014.

Antibodies and Conjugates
20th Annual Educational Course of the Swiss Society of Hematology, Zürich (Switzerland), 24 October 2014.

Current progress with armed antibody products.
Keynote Lecture at the PEGS Europe Conference, Lisbon (Portugal), 3 November 2014.

Antibody-based delivery of interleukin-2 to the neovasculature has potent activity against acute myeloid leukemia
Lecture for the Phoenix Award 2014 in Pharmacology and Clinical Pharmacy, Vienna (Austria), 6 November 2014.

Immunocytokines: clinical development and efficacy findings
European Antibody Congress, Geneva (Switzerland), 11 November 2014.

Monoclonal antibodies for cardiovascular applications
CardioMab Academy, Bologna (Italy), 27 November 2014.

Monoclonal antibodies in therapy.
Hyperlipidemia Academy, Vienna (Austria), 6 December 2014.

Immunocytokines for the therapy of cancer and of chronic inflammation
IBC's 25th Annual Antibody Engineering & Therapeutics Conference, Huntington Beach, CA (USA), 8 December 2014.

2015

The professor's view: how to support entrepreneurs during their PhD
Covagen's success story, ETH Spin-Off Event, Zürich (Switzerland), 23 January 2015

How to develop therapeutics in an academic context
Plenary Lecture at the Opening Symposium of the Drug Discovery Network Zürich (DDNZ), Zürich (Switzerland), 26 February 2015

Concept to clinic with novel immunocytokines
Keynote Lecture at the Symposium "Antibodies: an evolving force in cancer treatment, Royal Society of Medicine, London (UK), 11 March 2015

Molecular Imaging for the development of armed antibodies and of targeted cytotoxics: from the bench to the clinic.
Keynote Lecture at the ESMI/EMIM Congress, Tübingen (Germany), 19 March 2015

Antibody-cytokine fusion proteins: from the bench to the clinic
Keynote Lecture at the 1st International Symposium for Medicinal Sciences, 135th Annual Meeting of the Pharmaceutical Society of Japan, Kobe (Japan), 27 March 2015

Tumor Targeting: from the bench to the clinic
Keynote Lecture at the Cancer Network Zürich Retreat, Emmetten (Switzerland), 12 April 2015

Arming tumor-targeting antibodies with cytokine payloads: emerging clinical results
Lecture at a Major Symposium, AACR Annual Meeting, Philadelphia (U.S.A.), 21 April 2015

Arming antibodies for the therapy of cancer and of chronic inflammation: emerging clinical results
Lecture at the Department of Immunology, University of Tübingen, Tübingen (Germany), 28 April 2015

Drugs and Cytokines: synergistic payloads for monoclonal antibodies
Lecture at the Protein and Antibody Engineering Summit (PEGS), Boston (U.S.A.), 6 May 2015

Immunocytokines and targeted cytotoxics for cancer therapy
Lecture at the Royal Society, London (UK), 16 May 2015

Targeting tumors with armed antibodies and drug conjugates: from the bench to the clinic
Keynote Lecture at the Post-Doc Retreat of the University of Zürich, Au (Switzerland), 21 May 2015

Targeting the tumor sub-endothelial extracellular matrix with armed antibodies: from the bench to the clinic.
Lecture at the Scientific Symposium “Targeting tumor angiogenesis with antibody-based technologies”, Madrid (Spain), 8 June 2015

DNA-encoded chemical libraries and small molecule drug delivery
Lecture at the School of Organic Chemistry “A. Corbella”, Gargnano (Italy), 16 June 2015

Armed antibodies and targeted cytotoxics: from the bench to the clinic
Lecture at the EPFL/ETHZ Summer School on Translational Biology, Interlaken (Switzerland) 8 July 2015

Monoclonal antibodies: new options in diagnosis and therapy of CVD
PSK9forum Meeting, London (UK), 28 August 2015

Armed antibodies and targeted cytotoxics for cancer therapy
Keynote lecture at the Gesellschaft Deutscher Chemiker Congress, Dresden (Germany), 1 September 2015

Targeted delivery of bioactive payloads for the treatment of cancer and of chronic inflammation: from the bench to Phase II clinical trials
Lecture at Actelion, Allschwil (Switzerland), 17 September 2015

Armed antibodies and targeted cytotoxics for cancer therapy
Keynote Lecture at Adebiotech Symposium, Romainville (France), 24 September 2015

Armed antibodies and small molecule drug conjugates for cancer therapy

ECBS/ICBS Congress, Berlin (Germany), 8 October 2015

Towards a cure for cancer: chemotherapy or immunotherapy?
Cancer and Immunity: ask the Expert. Seminar Series at the University of Fribourg (Switzerland), 15 October 2015

Armed antibodies for the treatment of cancer and of chronic inflammation: from the bench to the clinic
Seminar at the Department of Medicine, University of Fribourg (Switzerland), 15 October 2015

Engineering armed antibodies for cancer therapy: from the bench to the clinic
19th International Conference on Human Antibodies & Hybridomas. Lausanne (Switzerland), 28 October 2015

DNA-encoded chemical libraries for the isolation of high-affinity binding ligands: an alternative to antibodies.
PEGS Europe, Lisbon (Portugal), 3 November 2015

Single-pharmacophore and dual-pharmacophore DNA-encoded chemical libraries: a comparative evaluation.
Keynote Lecture at the 1st Boston Symposium on Encoded Library Platforms. Waltham, MA (U.S.A.), 6 November 2015

Armed antibodies for the treatment of cancer and of chronic inflammation: from the bench to the clinic.
European Antibody Congress, Basel (Switzerland), 9 November 2015

Monoclonal antibodies – clinical experience.
2nd CEE Hyperlipidemia Meeting, Bratislava (Slovakia), 27 November 2015

2016

Armed antibodies for the treatment of cancer and of chronic inflammation: from the bench to the clinic.
Lecture in the “Neurology and MS research” seminar series, Klinik für Neurologie, University Hospital, Zürich (Switzerland), 20 January 2016

Translationale Forchung in der Arzneimittelentwicklung.
Lecture at the Swiss Society of Pharmacology and Toxicology meeting “Fortschritte in der Pharmakologie”. Bern (Switzerland), 28 January 2016

Armed antibodies for the treatment of cancer and of chronic inflammation
Lecture at the University of Aarhus (Denmark), 11 March 2016

Antibody-cytokine fusion proteins (immunocytokines) for targeted delivery: from bench to Phase III clinical trials
CHI Congress, London (UK), 16 March 2016

From encoded libraries to targeted therapeutics
Lecture at Servier, Croissy-sur-Seine (France), 13 April 2016

From encoded libraries to targeted therapeutics
Lecture at Roche, Basel (Switzerland), 19 April 2016

Immunocytokines for the treatment of cancer and of chronic inflammation
Lecture at the Protein and Antibody Engineering Summit (PEGS), Boston (U.S.A.), 26 April 2016

DNA-encoded chemical libraries
6th European Workshop on Drug Synthesis, Siena (Italy), 19 May 2016

Innovating targeting: the experience of Philogen from ligand discovery to Phase III clinical trials
Lecture at the "Giornata Didattica", Dottorato Regionale Pegaso in Biochemica e Biologia Molecolare, University of Siena, Siena (Italy), 19 May 2016

Quality aspects of therapeutic antibodies: Humira™ as a case study
ETH Postgraduate CAS Course on Quality and GMP, Module 3. Basel (Switzerland) 9 June 2016

Monoclonal antibodies: targeting the PCSK9 pathway
Satellite Symposium on the *Managing Hypercholesterolemia: Beyond Current Treatment Options*, SSC/SSCS-SSP, Lausanne (Switzerland) 16 June 2016

Ligand discovery and anti-cancer therapeutics: from the bench to the clinic
ISMB Symposium, Birkbeck College, London (UK) 30 June 2016

DNA-encoded chemical libraries
Keynote Lecture at the EFMC-ISMC International Symposium, Manchester (UK) 31 August 2016

Immunocytokines for cancer therapy: from the bench to the clinic
PIVAC Congress, Winchester (UK) 13 September 2016

Gli anticorpi monoclonali in cardiologia
Cardiovascular University training event, Milano (Italy) 20 September 2016

Antibody-cytokine fusions for the therapy of cancer and of chronic inflammation: from the bench to Phase III clinical trials
Keynote Lecture at the Congress of the German Pharmaceutical Society, Munich (Germany) 7 October 2016

Encoded combinatorial libraries for drug discovery
Lecture at Boehringer Ingelheim, Vienna (Austria) 13 October 2016

DNA-encoded chemical libraries: a tool for drug discovery
5th Lilly Chemistry Symposium, El Escorial (Spain) 28 October 2016

DNA-encoded chemical libraries

3rd ShanghaiTech-SIAIS Symposium, Shanghai (China) 9 November 2016

Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation
World Immunotherapy Congress, Basel (Switzerland) 14 November 2016.

Antibody-cytokine fusion proteins for the therapy of cancer and of chronic inflammation
Antibody Engineering & Therapeutics, San Diego, CA (U.S.A.) 14 December 2016.

2017

From encoded combinatorial libraries to targeted therapeutics
Lecture at the University of Pavia (Italy) 26 January 2017

From encoded combinatorial libraries to targeted therapeutics
Lecture at Bayer, Wuppertal (Germany) 2 February 2017

Investigations into mechanisms of immune tumor rejection
Immuno-Oncology Summit Europe, London (U.K.) 22 March 2017

Antibody-drug conjugates and small molecule-drug conjugates: a comparative evaluation
14th Symposium on Pharmacokinetics and Drug Metabolism, Swedish Pharmaceutical Society, Gothenburg (Sweden), 30 March 2017

Antibody-cytokine fusion proteins: from the bench to the clinic
Lecture in the Seminars in Translational Immunology (STIMM), University of Zürich (Switzerland), 5 April 2017

From encoded combinatorial libraries to targeted therapeutics
Lecture at the CNR Institute of Cell Biology, Monterotondo (Italy), 16 May 2017

Antibody-cytokine fusions: a novel class of biopharmaceuticals for the treatment of cancer and of chronic inflammation
Lecture at the 5th Heidelberg Forum for Young Life Science Scientists, Heidelberg (Germany), 9 June 2017

Ligand-based drug delivery in cancer and in chronic inflammation
Lecture at Seattle Genetics, Botham WA (U.S.A.), 12 June 2017

Focus on Engineered Antibodies
Lecture at the F.O.C.I.S. Congress, Chicago IL (U.S.A.), 14 June 2017

Antibody-cytokine fusions for the treatment of cancer and of chronic inflammation: from the bench to the clinic
Lecture at the Congress “Los Anticuerpos Monoclonales, el camino desde el laboratorio hasta el paciente“, Universidad Internacional Menendez Pelayo, Santander (Spain), 6 July 2017

Next-generation antibody-cytokine fusions: from the bench to the clinic
Lecture at Merck KgaA, Darmstadt (Germany), 28 August 2017

Antibody fusions for the therapy of cancer and of chronic inflammation
Lecture at GSK Vaccines, Siena (Italy), 4 September 2017

From encoded combinatorial libraries to targeted therapeutics
Lecture at SciForLife, Seminar Series, University (Sweden), 11 September 2017

Biologics: from academic idea to the clinic
Workshop "Life Science Community", SciForLife, Karolinska University, Stockholm (Sweden), 12 September 2017

From encoded combinatorial libraries to targeted therapeutics
Annual BMWZ Symposium, Centre of Biomolecular Drug Research, University of Hannover (Germany), 14 September 2017

From encoded combinatorial libraries to targeted therapeutics
38th Max-Bergmann-Konferenz, Reutlingen (Germany), 25 September 2017

From encoded combinatorial libraries to targeted therapeutics
Lecture at AstraZeneca, Mölndal (Sweden), 2 October 2017

Antibody-cytokine fusions for cancer therapy
World Immunotherapy Congress, Basel (Switzerland), 31 October 2017

Antibody-cytokine fusions: turning "cold" tumors "hot"
Lecture at Merck, Boston (U.S.A.), 6 November 2017

From encoded combinatorial libraries to targeted therapeutics
DTU Immunology Seminars Series, Technical University of Denmark, Copehagen (Denmark), 24 November 2017

Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: a comparative evaluation
Lecture at the Fall One-Day Thematic Symposium of the SCT (Conjugates and Drug Discovery Chemistry: new challenges for targeted therapies), Paris (France), 7 December

Kickstart the immune system with immunocytokines
Lecture at the ESMO Immuno Oncology Congress, Geneva (Switzerland), 8 December

2018

From encoded combinatorial libraries to targeted therapeutics
Lecture at the Department of Pharmacy, University of Bologna (Italy), 2 March 2018.

Antibody-cytokine fusion proteins: a novel class of immunotherapeutics for the treatment of cancer and of chronic inflammation
Second Annual Next-Generation Immuno-Oncology Congress, London (UK) 14 March 2018.

Antibody-cytokine fusion proteins: a novel class of immunotherapeutics for the treatment of cancer and of chronic inflammation

Lecture at the Institute of Oncology Research (IOR), Universita' della Svizzera Italiana, Bellinzona (Switzerland), 22 March 2018.

Protein-based therapeutics: different classes, different properties and different development processes for biosimilars
Pharma Horizonte 2018, Fribourg (Switzerland), 12 April 2018

Antibody-cytokine fusion proteins: from the bench to Phase III clinical trials
Spring Meeting of the Swiss Society of Pharmacology and Toxicology, Bern (Switzerland), 19 April 2018

Quality aspects of therapeutic antibodies: Humira™ as a case study
Postgraduate Course CAS Pharmaceuticals, Basel (Switzerland), 7 June 2018

From encoded libraries to clinical-stage targeted therapeutics
Lecture at the Novartis Institute for Functional Genomics, La Jolla (USA), 18 June 2018

Engineered antibodies for cancer therapy
Lecture at the FOCIS-SITC Congress, San Francisco (USA), 20 June 2018

Antibody-cytokine fusions for cancer therapy
Clinician Scientist Symposium on Translational Medicine, Berlin (Germany), 29 June 2018

Antibody-cytokine fusions: a novel class of biopharmaceuticals for the treatment of cancer and of chronic inflammation
Plenary Lecture at the European Congress of Biotechnology, Geneva (Switzerland), 2 July 2018

From encoded libraries to clinical-stage targeted therapeutics
Lecture at the FEBS 2018 Congress, Prague (Czech Republic), 11 July 2018

From encoded combinatorial libraries to targeted therapeutics
Buzzati-Traverso Lecture, EMBO Workshop on Enzymes, Biocatalysis and Chemical Biology, Pavia (Italy), 12 September 2018.

Encoded self-assembling chemical (ESAC) libraries
8th International Symposium on Encoded Chemical Libraries, Chengdu (China), 19 October 2018

Antibody-cytokine fusion proteins for cancer therapy
World Immunotherapy Congress, Basel (Switzerland), 29 October 2018

Impact of cytokine fusion proteins delivered to the tumor microenvironment
Lecture at PEGS Europe 2018, Lisbon (Portugal), 12 November 2018

Encoded Self-Assembling Chemical (ESAC) Libraries
Lecture at the 5th Bioforum Congress, ShanghaiTech, Shanghai (China), 15 November 2018

From encoded combinatorial libraries to clinical-stage targeted therapeutics
Lecture at the TU Dresden, Dresden (Germany), 13 December 2018

2019

A comparison between ADCs and SMDCs
2nd PSL ChemBiochem Symposium, Paris (France) 17 January 2019

Antibody-cytokine fusions for the treatment of cancer and of chronic inflammation
9th Alpbach Symposium, Alpbach (Austria) 11 March 2019

Next-generation antibody-cytokine fusion proteins
Immuno-Oncology Summit Europe, London (UK) 19 March 2019

Antibody-cytokine fusion proteins: from discovery to pivotal clinical trials
Lecture at PEGS Summit, Boston (U.S.A.) 8 April 2019

From encoded combinatorial libraries to targeted therapeutics
Bürgenstock Symposium, Brunnen (Switzerland) 8 May 2019

From encoded combinatorial libraries to targeted therapeutics
Genomec Seminar, Siena (Italy) 17 May 2019

Antibody-cytokine fusion proteins: from discovery to Phase III clinical trials
Danish Biotech Society, Vejle (Denmark) 28 May 2019

Antibody-based therapies
Lecture at SITC-FOCIS, Boston (U.S.A.) 18 June 2019

Immunocytokines for anti-cancer immunity
Fifty Shades of Immunology - 50th Anniversary of the Department of Clinical Immunology, University Hospital Zurich, Zurich (Switzerland), 2 July 2019

DNA-encoded chemical libraries
Seminar at Chiesi Farmaceutici, Parma (Italy), 1 October 2019

Antibody-cytokine fusion proteins: from discovery to Phase III clinical trials
Keynote Lecture at the Terrapinn Festival of Biologics, Basel (Switzerland) 15 October 2019

Combination of targeted cytokines with immune checkpoint inhibitors
Lecture at the Terrapinn Festival of Biologics, Basel (Switzerland) 15 October 2019

From encoded combinatorial libraries to targeted therapeutics
Keynote Lecture at the ICONAN Congress, Munich (Germany) 18 October 2019

From encoded combinatorial libraries to targeted therapeutics
Lecture at Genentech, South San Francisco (USA) 7 November 2019

Encoded combinatorial libraries: a revolution in the pharmaceutical industry
Lecture at Google, Mountain View (USA) 8 November 2019

Novel formats for antibody-cytokine fusion proteins: impact on performance

Keynote Presentation at PEGS Europe, Lisbon (Portugal) 19 November 2019

2020

Imaging and biodistribution analysis: a crucial tool for the development of targeted therapeutics.
Lecture at the École de Physique, Les Houches (France) 15 January 2020

Immunocytokines: impact of format on performance
Immuno-Oncology Summit Europe, London (UK) 9 March 2020

Antibody-cytokine fusions: from discovery to Phase III clinical trials
Immuno-Oncology Summit Europe, London (UK) 10 March 2020

Antibody-Drug Conjugates (ADCs) and Small Molecules-Drug Conjugates (SMDCs): a comparative analysis.
PEGS Boston Virtual Summit, 3 September 2020

Small Molecules-Drug Conjugates (SMDCs) and Antibody-Drug Conjugates (ADCs): a comparative evaluation.
World ADC Digital Conference, 17 September 2020

From encoded combinatorial libraries to targeted therapeutics
Chemists Live: an ACS Virtual Event, 25 September 2020.

Antibody-Drug Conjugates (ADCs) and Small Molecules-Drug Conjugates (SMDCs): a comparative evaluation.
CLINAM Virtual Congress. 28 October 2020

Cancer therapy using antibody-cytokine fusion proteins.
Next-Generation Protein Therapeutics and Bioconjugates Summit, Informa Virtual Event, 4 November 2020

Antibody-Drug Conjugates (ADCs) and Small Molecules-Drug Conjugates (SMDCs): a comparative evaluation.
PEGS Europe Virtual, Oncology Stream, 10 November 2020

Immunocytokines with “activity on demand”.
Keynote presentation at PEGS Europe Virtual, Immunotherapy Stream, 10 November 2020

Antibody-cytokine fusions: a novel class of biopharmaceuticals.
8th AIS 2020 Virtual: *Multispecific Antibodies, Ab-like Molecules & Adoptive Cell Therapy for Fighting Diseases*, 24 November 2020

2021

Antibody-cytokine fusions with “activity-on-demand”

Keynote Lecture at the “Cytokine-based cancer immunotherapies summit: a digital event”. Organized by Hanson-Wade. 24 March 2021.

From encoded libraries to clinical-stage targeted therapeutics.
Opening Lecture at the 13th Young Medicinal Chemist Virtual Symposium: “Nuove Prospettive in Chimica Farmaceutica”. 26 April 2021.

Antibody-drug conjugates (ADCs) and small molecule-drug conjugates (SMDCs): a comparative evaluation.
EFMC-ISMC 2021 International Symposium. 1 September 2021

DNA-encoded chemical libraries: from the bench to the clinic
Opening Lecture at the AGM Workshop on DNA-Encoded Libraries for Lead Discovery, National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health (NIH) [Virtual event]. 1 September 2021

Requirements for clinical translation
ImmunoTarget Workshop 2021. Zürich (Switzerland) 22 September 2021

Tumor Targeting
Keynote Presentation at the Scientific Retreat 2021 of the Department of Medical Oncology and Hematology of the University Hospital Zurich. Davos (Switzerland) 26 September 2021

Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for cancer therapy
VII Forum de Terapia Translacional e Inmunoterapia del Cáncer [Virtual event]. 30 September 2021

From encoded combinatorial libraries to targeted therapeutics
Invited Lecture at AstraZeneca [Virtual event]. 22 October 2021

From encoded combinatorial libraries to targeted therapeutics
Joint Prague-Weizmann School on Drug Discovery [Virtual event]. 25 October 2021

Next-generation antibody-cytokine fusions for cancer therapy
13th Annual PEGS Europe: Protein and Antibody Engineering Summit. Barcelona (Spain) 4 November 2021

Antibody-cytokine fusions for cancer therapy with “activity-on-demand”
Festival of Biologics, Basel (Switzerland) 10 November 2021

Antibody-cytokine fusions: from discovery to Phase III clinical trials
Keynote lecture at the Festival of Biologics, Basel (Switzerland) 11 November 2021

Tripokin: a potency-matched dual cytokine fusion for cancer therapy
Lecture at the Antibody Engineering and Therapeutics Congress, San Diego (U.S.A.) 15 December 2021

2022

DNA-encoded small molecules for drug delivery/imaging
GDS Drug Discovery Symposium (Virtual Event), 3 February 2022

From encoded combinatorial libraries to clinical-stage therapeutics
Lecture at the Accademia dei Lincei, Rome (Italy), 18 March 2022

From encoded combinatorial libraries to clinical-stage therapeutics
Lecture at the Department of Pharmaceutical Science, University of Basel, Basel (Switzerland), 23 March 2022

Modulating the therapeutic activity of ADCs and SMDCs with engineered cytokine products
Lecture at the 12th ADC World London, London (UK), 31 March 2022

Antibody-cytokine fusions: from the bench to the clinic
Lecture at AMC University, Amsterdam (The Netherlands), 5 April 2022

From encoded combinatorial libraries to clinical-stage therapeutics
Lecture at Imperial College, London (UK) 10 May 2022

Antibody-cytokine fusions as bispecific immunomodulatory proteins
Oncology Summit Europe, London (UK), 24 March 2022

Philogen: a Swiss-Italian Biotech Company
Presentation at the UBS Healthcare Conference, New York (U.S.A.), 25 March 2022

Antibody-cytokine fusions for the treatment of cancer and of chronic inflammation
Lecture at the "Delivery of Macromolecules" Informa Congress (Virtual Symposium), 8 June 2022

FAP: the target of the century
Lecture at the Annual ImmunoTarget/ImmunoCure Meeting, Zurich (Switzerland) 17 June

Pharmaceutical Innovation out of Academia
Lecture at the 30th ECPM Conference, Basel (Switzerland), 20 June 2022

From encoded combinatorial libraries to targeted therapeutics
Lecture at Bicycle Therapeutics, Cambridge (UK), 22 June 2022

From encoded combinatorial libraries to clinical-stage radiopharmaceuticals
Lecture at the Department of Radiology, University of Cambridge, Cambridge (UK), 22 June 2022

Pharmaceutical Innovation in Industry and Academia: a personal perspective
R&D Management Conference, University of Trento (Italy), 11 July 2022

From Encoded Combinatorial Libraries to Clinical-Stage Targeted Therapeutics
Lecture at KTH, Stockholm (Sweden), 6 October 2022

From Encoded Combinatorial Libraries to Clinical-Stage Targeted Therapeutics
Lecture at IQS, Barcelona (Spain), 14 October 2022

Quantification of DEL selections and implications for good selection protocols
Lecture at the 10th Symposium on Encoded Combinatorial Libraries, The Broad Institute, Cambridge MA (USA), 3 November 2022

Antibody-Cytokine Fusions: emerging clinical data in glioblastoma, sarcoma and dermato-oncology indications
Lecture at PEGS Europe, Barcelona (Spain), 14 November 2022

Implementing "Antivity-on-Demand" strategies with bispecifics and antibody-cytokine fusions
Lecture at PEGS Europe, Barcelona (Spain), 15 November 2022

From encoded chemical libraries to clinical-stage targeted therapeutics
Lecture at the Department of Rheumatology, Amsterdam University Medical Center, Amstrdam (The Netherlands), 25 November 2022

From encoded chemical libraries to clinical-stage targeted therapeutics
Lecture at Istituto Oncologico di Ricerca, Bellinzona (Switzerland), 28 November 2022

Small Molecule-Drug Conjugates (SMDCs) and Antibody-Drug Conjugates (ADCs): a comparative evaluation
Lecture at the Antibody Engineering & Therapeutics 2022 Congress, San Diego CA (U.S.A.), 6 December 2022

2023

From encoded combinatorial libraries to clinical-stage targeted therapeutics
LED3 Seminary (Leiden Early Drug Discovery and Development) at the University of Leiden (The Netherlands), 23 February 2023

Novel developments on immunocytokines
Lecture at the Mosbacher Kolloquium, Mosbach (Germany), 23 March 2023

Innovative targeted therapies in Oncology (and beyond)
Lecture at EADO, Rome (Italy), 21 April 2023

From encoded combinatorial libraries to targeted therapeutics
Lecture at the University of Siena (Italy), 9 May 2023

Antibody-cytokine fusions for the treatment of difficult-to-cure cancer types: emerging clinical results
Lecture PEGS Boston, Boston MA (U.S.A.), 18 May 2023

From encoded combinatorial libraries to clinical-stage targeted therapeutics
Lecture at the Lund Spring Symposium "Enabling Novel Therapeutic Principles", 24 May 2023

Immunocytokines with activity-on-demand
Lecture at the Antibody Europe Informa Congress in Amsterdam (The Netherlands), 6 June 2023

From encoded combinatorial libraries to targeted therapeutics
Lecture at the Technische Universität Darmstadt in the frame of the MAGICBULLET RELOADED Consortium, Darmstadt (Germany), 25 August 2023

DNA-encoded chemical libraries: past, present and future
Lecture at the 11th Symposium on Encoded Combinatorial Libraries (DEL Symposium), ETH Zürich, Zurich (Switzerland) 7 September 2023

The dream of Paul Ehrlich
Award Lecture for the Pratesi Medal of the Italian Chemical Society, Chieti (Italy), 17 September 2023

Antibody-toxin conjugates
Lecture at the ITID Conference, Bellinzona (Switzerland), 27 September 2023

Antibody-cytokine fusions for cancer therapy
Lecture at the Festival of Biologics, Basel (Switzerland), 10 October 2023

Tumor Targeting: From Encoded Libraries to Clinical-Stage Therapeutics
Distinguished Ludwig Cancer Center Seminar, Lausanne (Switzerland), 1 November 2023

Tumor targeting
EFMC Symposium on Chemical Biology, Basel (Switzerland), 16 November 2023

Tumor targeting
Lecture at Engitix, London (UK), 17 November 2023

From encoded combinatorial libraries to clinical-stage targeted therapeutics
Lecture in Arcachon (France), 23 November 2023

5) List of Publications

1 - A. Carpita, **D. Neri**, R. Rossi (1987) "Stereocontrolled synthesis of naturally-occurring polyacetylenes characterized by (E)-1-en-3-yne, (E)-1-en-3,5-diyne, (1E,5E)-1,5-dien-3-yne, and (1E,7E)-1,7-dien-3,5-diyne moieties". *Gazz. Chim. Ital.* **117**, 481-489.

2 - A. Carpita, **D. Neri**, R. Rossi (1987) "Regio- and Stereo-selective synthesis of (2E,6E,8E)-N-(2-methylpropyl)-2,6,8-hexadecatrien-10-ynamide, a naturally-occurring acetylenic substance". *Gazz. Chim. Ital.* **117**, 503-505.

3 - J.B. Hudson, E.A. Graham, N. Miki, G.H.N. Towers, L.L. Hudson, R. Rossi, A. Carpita, **D. Neri** (1989) "Photoactive antiviral and cytotoxic activities of synthetic thiophenes and their acetylenic derivatives". *Chemosphere* **19**, 1329-1343.

4 - J.B. Hudson, G.H.N. Towers, Z. Abramowski, L. Hudson, R. Rossi, A. Carpita, **D. Neri** (1989) "Ultraviolet-mediated antibiotic activity of synthetic thiophenes and their acetylenic derivatives". *Chemosphere* **18**, 2317-2327.

5 - G. Wider, **D. Neri**, G. Otting, K. Wüthrich (1989) "A heteronuclear three-dimensional NMR experiment for measurementes of small heteronuclear coupling constants in biological macromolecules". *J. Magn. Reson.* **85**, 426-431.

6 - D. Neri, T. Szyperski, G. Otting, H. Senn, K. Wüthrich (1989) "Stereospecific Nuclear Magnetic Resonance assignments of the methyl groups of valine and leucine in the DNA-binding domain of the 434 repressor by biosynthetically directed fractional ^{13}C labeling". *Biochemistry* **28**, 7510-7516.

7 - D. Neri, G. Otting, K. Wüthrich (1990) "^{1}H and ^{13}C chemical shifts of the diastereotopic methyl groups of valyl and leucyl residues in peptides and proteins". *Tetrahedron* **46**, 3287-3296.

8 - D. Neri, G. Otting, K. Wüthrich (1990) "New Nuclear Magnetic Resonance experiment for measurements of the vicinal coupling constants $^{3}J_{HN\alpha}$ in proteins". *J. Am. Chem. Soc.* **112**, 3663-3665.

9 - G. Wider, **D. Neri**, K. Wüthrich (1991) "Studies of slow conformational equilibria in macromolecules by exchange of heteronuclear longitudinal 2-spin-order in a 2D difference correlation experiment". *J. Biomol. NMR* **1**, 93-98.

10 - M. Billeter, **D. Neri**, G. Otting, Y.Q. Qian, K. Wüthrich (1992) "Precise vicinal coupling constants $^{3}J_{HN\alpha}$ in proteins from nonlinear fits of J-modulated [^{15}N-^{1}H]-COSY experiments". *J. Biomol. NMR* **2**, 257-274.

11 - T. Szyperski, **D. Neri**, B. Leiting, G. Otting, K. Wüthrich (1992) "Support of ^{1}H NMR assignments in proteins by biosynthetically-directed fractional ^{13}C-labeling". *J. Biomol. NMR* **2**, 323-334.

12 - D. Neri, M. Billeter, K. Wüthrich (1992) "Determination of the Nuclear Magnetic Resonance solution structure of the DNA-binding domain (residues 1-69) of the 434 repressor and comparison with the X-ray crystal structure". *J. Mol. Biol.* **223**, 743-767.

13 - D. Neri, G. Wider, K. Wüthrich (1992) "Complete ^{15}N and ^{1}H NMR assignments for the amino-terminal domain of the phage 434 repressor in the urea-unfolded form". *Proc. Natl. Acad. Sci. U.S.A.* **89**, 4397-4401.

14 - D. Neri, G. Wider, K. Wüthrich (1992) "^{1}H, ^{15}N and ^{13}C NMR assignments of the 434 repressor fragments 1-63 and 44-63 unfolded in 7 M urea". *FEBS Lett.* **303**, 129-135.

15 - D. Neri, M. Billeter, G. Wider, K. Wüthrich (1992) "NMR determination of residual structure in a urea-denatured protein, the 434 repressor". *Science* **257**, 1559-1563.

16 – J.B. Hudson, E.A. Graham, R. Rossi, A. Carpita, **D. Neri**, G.H. Towers (1993) "Biological activities of terthiophenes and polyynes from the Asteraceae". *Planta Med.* **59**, 447-450.

17 - R. Vola, A. Lombardi, L. Tarditi, M. Zaccolo, **D. Neri**, L. Björck and M. Mariani (1994). Recombinant proteins L and LG: two new tools for purification of murine antibody fragments. *Cell Biophys.*, **24/25**, 27-36.

18 - D. Neri, C. de Lalla, H. Petrul, P. Soldani, A. di Stefano, L. Lozzi, G. Neri, P. Neri (1995) "Engineering bifunctional recombinant antibodies". *Tumor Targeting*, **1**, 189-194.

19 - D. Neri, M. Momo, T. Prospero, G. Winter (1995) "High-affinity antigen binding by chelating recombinant antibodies (CRAbs)". *J. Mol. Biol*, **246**, 367-373.

20 - D. Neri, C. de Lalla, H. Petrul, P. Neri, G. Winter (1995) "Calmodulin as a versatile tag for antibody fragments". *Bio/Technology*, **13**, 373-377.

21 - D. Neri, H. Petrul and G. Roncucci (1995) "Engineering recombinant antibodies for immunotherapy". *Cell Biophys.*, **27**, 47-61.

22 - D. Neri, S. Montigiani and P. Neri (1995) "Thermodynamic and kinetic characterisation of high-affinity recombinant antibodies binding to their antigen". *Tumor Targeting*, **1**, 259-266.

23 - M. Liberatore, **D. Neri**, G. Neri, A. Pini, A.P. Iurilli, F. Ponzo, G. Spampinato, F. Padula, A. Pala and A. Centi Colella (1995) "Efficient one-step direct labeling of recombinant antibodies with ^{99m}Tc". *Eur. J. Nuclear Med.*, 22, 1326-1329.

24 - D. Neri, T. Prospero, H. Petrul, G. Winter, M. Browne, L. Vanderpant (1996) "A multi-purpose high-sensitivity luminescence analyser (LUANA): use in gel electrophoresis". *Bio/Techniques*, **20**, 708-713.

25 - D. Neri, H. Petrul, G. Winter, Y. Light, R. Marais, K.E. Britton, A.M. Creighton (1996) "Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase II and [γ-^{32}P]-ATP". *Nature Biotechnology*, **14**, 485-490.

26 - S. Montigiani, G. Neri, P. Neri, **D. Neri** (1996) "Alanine substitutions in calmodulin-binding peptides result in unexpected affinity enhancement". *J. Mol. Biol.*, **258**, 6-13.

27 - D. Neri, P.G. Natali, H. Petrul, P. Soldani, R. Vola, M.R. Nicotra, A. Rivella, A.M. Creighton, P. Neri, G. Winter, M. Mariani (1996) "Recombinant anti human melanoma antibodies can be functionalised efficiently". *J. Invest. Dermatol.*, **107**, 164-170.

28 - Carnemolla, B., **Neri, D**., Castellani, P., Leprini, A., Neri, G., Pini, A., Winter, G. and Zardi, L. (1996) Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. *Int. J. Cancer*, **68**, 397-405.

29 - B. Cosimelli, **D. Neri**, G. Roncucci (1996) "A new synthetic route to 2,2':5',5"-terthiophene-5-derivatives to conjugate with proteins and monoclonal antibodies". *Tetrahedron*, **52**, 11281-11290.

30 - **D. Neri**, S. Montigiani and P.M.Kirkham (1996) "Biophysical methods for the determination of antibody-antigen affinities". *Trends in Biotechnol.*, **14**, 465-470.

31 - G. Mariani, A. Lasku, E. Balza, B. Gaggero, C. Motta, L. Di Luca, A. Dorcaratto, G.A. Viale, **D. Neri**, L. Zardi (1997). "Tumour targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumour implants". *Cancer*, 80, 2378-2384.

32 - A. Pini, A. Spreafico, R. Botti, **D. Neri** and P. Neri (1997). "Hierarchical affinity maturation of a phage library derived antibody for the selective removal of cytomegalovirus from plasma". *J. Immunol. Meth.*, 206, 171-182.

33 - D. Neri, B.Carnemolla, A. Nissim, E. Balza, A. Leprini, G. Querze', A. Pini, L. Tarli, C. Halin, P. Neri, L. Zardi, G. Winter (1997) " Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform". *Nature Biotechnology*, 15, 1271-1275.
(Analysis at page 1243-4).

34 - **D. Neri**, L. Zardi (1997). "New approaches to tumour targeting"; in *"Therapy of malignancies with radio-conjugate monoclonal antibodies: present possibilities and future perspectives".* Riva P., editor, Harwood Academic Publishers GmbH.

35 - D. Neri, L. Zardi (1998) "Affinity reagents against tumor-associated extracellular molecules and new-forming vessels". *Adv. Drug Deliv. Reviews*, 31, 43-52.

36 - D. Neri, A. Pini, A. Nissim (1998) "Antibodies from phage display libraries as immunochemical reagents" *Methods Mol. Biol.*, 80, 475-500.

37 - L. Borsi, P. Castellani, G. Allemanni, **D. Neri**, L. Zardi (1998). "Preparation of phage antibodies to the ED-A domain of human fibronectin, mediator of hepatic fibrogenesis". *Exp. Cell Res.*, 240, 244-251.

38 - A. Pini, F. Viti, A. Santucci, B. Carnemolla, L. Zardi, P. Neri, **D. Neri** (1998). "Design and use of a phage-display library: human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel". *J. Biol. Chem.*, 273, 21769-21776.

39 - P. Kirkham, **D. Neri** and G. Winter (1999). "Towards the design of an antibody that recognises a given epitope". *J. Mol. Biol.*, 285, 909-915.

40 - F. Viti, L. Tarli, L. Giovannoni, L. Zardi, **D. Neri** (1999). "Binding affinity and valence determine the tumour targeting performance of anti-angiogenesis antibodies". *Cancer Res.*, 59, 347-352.

41 - B. Carnemolla, P.Castellani, M. Ponassi, L. Borsi, S. Urbini, G. Nicolo', A. Dorcaratto, G. Viale, G. Winter, **D. Neri** and L. Zardi (1999). "Identification of a glioblastoma associated TN-C isoform by a high affinity recombinant antibody". *Am. J. Pathol.*, 154, 1345-1352.

42 - S. Demartis, A. Huber, F. Viti, L. Giovannoni, L. Lozzi, P. Neri, G. Winter, **D. Neri** (1999). "A strategy for the isolation of catalytic activities from repertoires of enzymes displayed on phage". *J. Mol. Biol.*, 286, 617-633.

43 - R. Fattorusso, M. Pellecchia, F. Viti, P. Neri, **D. Neri**, K. Wüthrich (1999). "NMR structure of the angiogenesis marker oncofoetal fibronectin ED-B domain". *Structure Fold. Des.*, 7, 381-390.

44 - A. Huber, S. Demartis, **D. Neri** (1999) "The use of biosensor technology for the engineering of antibodies and enzymes". *J. Mol. Recogn.*, 12, 198-216.

45 - L. Tarli, E. Balza, F. Viti, L. Borsi, P.Castellani, D. Berndorff, L. Dinkelborg, **D. Neri***, L. Zardi (1999). "A high-affinity human antibody that targets tumoural blood vessels ". *Blood*, 94, 192-198. [* = corresponding author]

46 – M. Birchler, F. Viti, L. Zardi, B. Spiess, **D. Neri** (1999). "Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived recombinant antibody". *Nature Biotechnol.*, 17, 984-988.

47 – M. Birchler, G. Neri, L. Tarli, F. Viti, **D. Neri** (1999). "Infrared photodetection for the in vivo localisation of phage derived antibodies directed against angiogenic markers". *J. Immunol. Methods*, 231, 239-248.

48 - F. Nilsson, L. Tarli, F. Viti, M. Birchler, **D. Neri** (2000) "The use of phage display for the development of tumour targeting agents". *Adv. Drug Deliv. Reviews*, 43, 165-196.

49 - L. Giovannoni, L. Lozzi, **D. Neri**, P. Neri (2000). "Highly fluorescent protein labeling using dendritic peptide derivatives". *J. Pept. Res.*, 55, 195-200.

50 - F. Viti, F. Nilsson, S. Demartis, A. Huber, **D. Neri** (2000). "Design and use of phage display libraries, for the selection of antibodies and enzymes". *Methods in Enzymology*, 326, 480-505.

51 – F. Viti, M. Bumke, M. Silacci, L. Zardi, **D. Neri** (2000). "A strategy for the identification of differentially expressed proteins secreted by fibroblasts". *Chimia*, 54, 678-682.

52 – A. Vitaliti, M. Wittmer, R. Steiner, L. Wyder, **D. Neri**, R. Klemenz (2000). Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. *Cancer Res*., 60, 4311-4314.

53 - F. Nilsson, H. Kosmehl, L. Zardi, **D. Neri** (2001). "Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumours in mice", *Cancer Res.*, 61, 711-716. [also featured on the Cover]

54 – C. Halin, **D. Neri** (2001). "Antibody-based targeting of angiogenesis". *Crit. Rev. Ther. Drug Carrier Syst*., 18, 299-339.

55 – L. Giovannoni, F. Viti, L. Zardi, **D. Neri** (2001). "Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening". *Nucleic Ac. Res*., 29, No.5, e27.

56 – F. Viti, P. Pedrioli, B. Mitta, **D. Neri** (2001). "Phage display libraries as a source of tumour-targeting agents". *Chimia*, 55, 206-211.

57 – M. Bumke, **D. Neri** (2001). "Affinity measurements by competition ELISA and band shift experiments". Chapter in *Antibody Engineering*, Eds. S.Dübel and R. Kontermann, Springer-Verlag, Berlin, pp. 385-396.

58 – S. Demartis, L. Tarli, L. Borsi, L. Zardi, **D. Neri** (2001). In vivo targeting of tumour neo-vasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. *Eur. J. Nucl. Med*., 28, 534-539.

59 – C. Halin, L. Zardi, **D. Neri** (2001). "Antibody-based targeting of angiogenesis". *News Physiol. Sci*., 16, 191-194.

60 – A. Desiderio, R. Franconi, M. Lopez, M.E. Villani, F. Viti, R. Chiaraluce, V. Consalvi, **D. Neri**, E. Benvenuto (2001). "A semi-synthetic repertoire of intrinsically stable antibody fragments derived from a single-framework scaffold". *J. Mol. Biol*., 310, 605-617.

61 - E. Balza, P. Castellani, A. Zijlstra, **D. Neri**, L. Zardi, A. Siri (2001) "Lack of specificity of endoglin for tumor blood vessels". *Int. J. Cancer*, 94, 579-585

62 – M. Nakayama, **D. Neri**, O. Ohara (2001) "A new simplified method for preparation of a synthetic phage antibody with practically acceptable detection sensitivity on immunoblots". *Human Antibodies*, 10, 55-65.

63 – C. Heinis, A. Huber, S. Demartis, J. Bertschinger, S. Melkko, L. Lozzi, P. Neri, **D. Neri** . (2001) "Selection of catalytically active biotin ligase and trypsin mutants by phage display". *Protein Engineering*, 14, 1043-1052.

64 – C. Heinis, S. Melkko, S. Demartis, **D. Neri** (2002) "Two general methods for the isolation of enzyme activities by colony filter screening". *Chemistry and Biology*, 9, 383-390.

65 – B. Carnemolla, L. Borsi, E. Balza, P. Castellani, R. Meazza, A. Berndt, S. Ferrini, H. Kosmehl, **D. Neri**, L. Zardi. (2002) "Enhancement of the anti-tumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix". *Blood*, 99, 1659-1665.

66 – C. Halin, S. Rondini, F. Nilsson, A. Berndt, H. Kosmehl, L. Zardi, **D. Neri** (2002) "Enhancement of the anti-tumor activity of interleukin-12 by targeted delivery to neo-vasculature". *Nature Biotechnol.*, 20, 264-269.

67 – F. Viti, L. Giovannoni, **D. Neri** (2002) "Recombinant antibodies for the selective targeting of tumor neo-vasculature". *Current Opinion in Drug Discovery and Development*, 5, 204-213.

68 – U. Niesner, C. Halin, L. Lozzi, M. Güntert, P. Neri, H. Wunderli-Allenspach, L. Zardi, **D. Neri** (2002) „Quantitation of the tumor targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides"*Bioconj. Chem.*, 13, 729-736.

69 – C. Marty, B. Odermatt, H. Schott, **D. Neri**, K. Ballmer-Hofer, R. Klemenz, R.A. Schwendener (2002). „Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes". *Br. J. Cancer*, 87, 106-112.

70 – G. Elia, M. Silacci, M. Bumke, S. Scheurer, **D. Neri** (2002). „Visualizing the proteome in structurally intact samples". *BioWorld* 3, 16-17.

71 – C. Halin, U. Niesner, M.E. Villani, L. Zardi, **D. Neri** (2002). „Tumor targeting properties of antibody-VEGF fusion proteins". *Int. J. Cancer*, 102, 109-116.

72 – S. Melkko, C. Halin, L. Borsi, L. Zardi, **D. Neri** (2002). „An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance". *Int. J. Rad. Oncol. Biol. Phys.*, 54, 1485-1490.

73 – P. Castellani, L. Borsi, B. Carnemolla, A. Biro, A. Dorcaratto, G. L. Viale, **D. Neri**, L. Zardi (2002). „Differentiation between high and low grade astrocytoma using a human recombinant antibody to the ED-B domain of fibronectin". *Am. J. Pathol.*, 161, 1695-1700.

74 – L. Borsi, E. Balza, M. Bestagno, P. Castellani, B. Carnemolla, A. Biro, A. Leprini, J. Sepulveda, O. Burrone, **D. Neri**, L. Zardi (2002). „Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin". *Int. J. Cancer*, 102, 75-85.

75 – G. Elia, M. Silacci, S. Scheurer, J. Scheuermann, **D. Neri** (2002). „Affinity capture reagents for protein arrays". *Trends in Biotechnology*, 20, No. 12 (Suppl.) S19-S22.

76 – M. Nicolo', A. Biro, F. Cardillo-Piccolino, P. Castellani, A. Giovannini, C. Mariotti, M. Zingirian, **D. Neri**, L. Zardi (2003) "Expression of the ED-B containing fibronectin in subretinal choroidal neovascular membranes". *Am. J. Ophthalm.*, 135, 7-13.

77 – M.A. Bumke, **D. Neri***, G. Elia (2003). „Modulation of gene expression by extracellular pH variations in human fibroblasts. A transcriptomic and proteomic study". *Proteomics*, 3, 675-88. [* = corresponding author]

78 – M. Santimaria, G. Moscatelli, G.L. Viale, L. Giovannoni, G. Neri, F. Viti, A. Leprini, L. Borsi, P. Castellani, L. Zardi, **D. Neri**, P. Riva (2003). „Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer". *Clin. Cancer Res.*, 9, 571-579. [also featured on the Cover]

79 – S. Melkko, **D. Neri** (2003) „ Calmodulin as an affinity purification tag." *Methods Mol Biol.*, 205, 69-77.

80 – F.O. Lösch, R. Müller, B. Mutschler, **D. Neri**, P.G. Natali, M. Reth, R. Carsetti (2003) „Activation of T cells via tumor antigen specific chimeric receptors: The role of the intracellular signaling domain". *Int J Cancer*, 103, 399-407.

81 – J. Scheuermann, A. Volonterio, O. Zerbe, M. Zanda, **D. Neri** (2003) „Discovery and investigation of lead-compounds as binders to the extra-domain B of fibronectin, a marker of angiogenesis". *Drug Development Research*, 58, 268-282.

82 – J. Scheuermann, F. Viti, **D. Neri** (2003) „ Unexpected observation of concentration-dependent dissociation rates for antibody-antigen complexes and other macromolecular complexes in competition experiments". *J. Immunol. Methods*, 276,129-134.

83 – C. Halin, V. Gafner, M.E. Villani, L. Borsi, A.Berndt, H. Kosmehl, L. Zardi, **D. Neri** (2003) "Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin-12 and to tumor necrosis factor alpha". *Cancer Res.*, 63, 3202-3210.

84 – C. Heinis, J. Bertschinger, **D. Neri** (2003) "Calmodulin-tagged phage and two-filter sandwhich assays for the identification of enzymatic activities". in "Directed Enzyme Evolution". *Methods Mol Biol.* 230, 313-328

85 – M.T. Birchler, D. Milisavlijevic, M. Pfaltz, **D. Neri**, B. Odermatt, S. Schmid, S.J. Stoeckli (2003). "Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors". *Laryngoscope.* 113, 1231-1237.

86 - L. Borsi, E. Balza, B. Carnemolla, F. Sassi, P. Castellani, A. Berndt, H. Kosmehl, A. Biro, A. Siri, P. Orecchia, J. Grassi, **D. Neri**, L. Zardi (2003) "Selective targeted delivery of TNF{alpha} to tumor blood vessels". *Blood*, 102, 4384-4392.

87 – T.A. Afanasieva, M. Wittmer, A. Vitaliti, M. Ajmo, **D. Neri**, R. Klemenz (2003) "Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy. *Gene Ther.* 10, 1850-1859.

88 – P.A. Binz , F. Abdi, M. Affolter, L. Allard, J. Barblan, S. Bhardwaj, W.V. Bienvenut, P. Bulet, J. Burgess, O. Carrette, G. Corthals, F. Delalande, H. Diemer, P. Favreau, G. Elia, Y. Gueguen, E. Guillaume, S. Hahner, P. Man, S. Michalet, **D. Neri**, D. Noukakis, P. Palagi, P. Paroutaud, D. Carvalho Pimenta, M. Quadroni, A. Resemann, S. Richert, J. Rybak, J.C. Sanchez, A. Scherl, S. Scheurer, U. Schweiger Hufnagel, C. Siethoff, D. Suckau, A. Van Dorsselaer, W. Wagner Redeker, N. Walter, R. Stocklin (2003) "Proteomics application exercise of the Swiss Proteomics Society: Report of the SPS'02 session". *Proteomics*, 3, 1562-1566.

89 – **D. Neri**, L. Zardi (2003) "Angiogenesis: molecular imaging". Chapter of the book "MRI" from current knowledge to new horizons", Eds J.F. Debatin, H. Hricak, H.P. Niendorf, Excerpta Medica Communications BV, The Netherlands.

90 – P. Alessi, C. Ebbinghaus, **D. Neri** (2004) "Molecular targeting of angiogenesis" *Biochim. Biophys. Acta Rev. Cancer*, 1654, 39-49.

91 – S. Scheurer, J. Rybak, C. Rösli, **D. Neri***, G. Elia (2004) "Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells. A transcriptomic and proteomic study". *Proteomics*, 4, 1737-1760. [* = corresponding author]

92 – S. Scheurer, J. Rybak, C. Rösli, G. Elia, **D. Neri** (2004) "Antibody-based vascular targeting: proteomic techniques for the identification and quantification of membrane proteins on endothelial cells". Chapter of the book "Biomedical Applications of Proteomics", Eds. J.C. Sanchez, G.L. Corthals, D.F. Hochstrasser. Wiley-VCH, Germany.

93 - J. Rybak, S. Scheurer, **D. Neri***, G. Elia (2004) "Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution". *Proteomics*, 4, 2296-2299 [* = corresponding author]

94 - S. Melkko, J. Scheuermann, C. Dumelin, **D. Neri** (2004) "Encoded self-assembling chemical libraries". *Nature Biotechnol.*, 22, 568-574.

95 – C. Heinis, P. Alessi, **D. Neri** (2004) "Engineering a thermostable human prolyl endopeptidase for antibody directed enzyme prodrug therapy (ADEPT)". *Biochemistry*, 43, 6293-6303.

96 – C.M. Matter, P.K. Schuler, P. Alessi, P. Meier, R. Ricci, D. Zhang, C. Halin, P. Castellani, L. Zardi, C.K. Hofer, M. Montani, **D. Neri***, T.F. Luscher (2004) Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. *Circ. Res.*, 95, 1225-1233. [* = corresponding author]

97 – S.S. Brack, L.M. Dinkelborg, **D. Neri** (2004) "Molecular targeting of angiogenesis for imaging and therapy". *Eur J Nucl Med Mol Imaging.*, 31, 1327-1341.

98 – J. Bertschinger and **D. Neri** (2004) "Covalent DNA display as a novel tool for directed evolution of proteins in vitro". *Protein Eng. Des. Sel.*, 17, 699-707

99 – C. Ebbinghaus, J. Scheuermann, **D. Neri**, G. Elia (2004) " Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. *Curr. Pharm. Des.*, 10, 1537-1549.

100 – **D. Neri** (2004) "Tumor Targeting". *CHIMIA*, 58, 723-726.

101 – C. Ebbinghaus, R. Ronca, M. Kaspar, D. Grabulovski, A. Berndt, H. Kosmehl, L. Zardi, and **D. Neri** (2005) "An engineered vascular-targeting antibody-interferon gamma fusion protein for cancer therapy" *Int. J. Cancer*, 116, 304-313.

102 – S. Scheurer, J. Rybak, C. Rösli, **D. Neri***, G. Elia (2005). "Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping". *Proteomics*, 5, 3035-3039.[* = corresponding author]

103 – M. Silacci, S. Brack, G. Schirru, J. Mårlind, A. Ettorre, A. Merlo, F. Viti, **D. Neri** (2005) Design, construction, and characterization of a large synthetic human antibody phage display library. *Proteomics*, 5, 2340-2350

104 – J. Rybak, B. Kaissling, R. Giavazzi, **D. Neri***, G. Elia (2005). "In vivo protein biotinylation for the identification of organ-specific antigens accessible from the vasculature". *Nature Methods*, 2, 291-298 [* = corresponding author] (also featured on the Cover)

105 - D. Neri and R. Bicknell (2005) "Vascular tumor targeting". *Nature Rev. Cancer*, 5, 436-446

106 – S. Melkko, J. Sobek, G. Guarda, J. Scheuermann, C.E. Dumelin and **D. Neri** (2005) "Encoded self-assembling chemical libraries". *CHIMIA*, 59, 798-802.

107 – M. Silacci and **D. Neri** (2005) "Ligand-based targeting of disease: from antibodies to small organic synthetic ligands". Modern Biopharmaceuticals Vol. 3. Design, Development and Optimization. Edited by Jörg Knäblein, Wiley-VCH Verlag, Berlin, 2005

108 – M. Fabbrini, E. Trachsel, P. Soldani, S. Bindi, P. Alessi, L. Bracci, H. Kosmehl, L. Zardi, **D. Neri***, P. Neri (2006) "Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate". *Int J Cancer*, 118, 1805-1813 [* = corresponding author]

109 – J. Bertschinger, C. Heinis and **D. Neri** (2005) "Selections for enzymatic catalysts". Phage Display in Biotechnology and Drug Discovery. Edited by Sachdev S. Sidhu, CRC Press, Taylor&Francis Group, Boca Raton, 2005.

110 – M. Kaspar, L. Zardi and **D. Neri** (2006) "Fibronectin as a target for tumor therapy". *Int. J. Cancer*, 118, 1331-1339.

111 – **D. Neri**, G. Fossati and M. Zanda (2006) "Efforts toward the total synthesis of tubulysins, potent cytotoxic natural tetrapeptides: new hopes for a more effective targeted drug delivery to tumors " *ChemMedChem*, 1, 175-180.

112 – S. Melkko, C.E. Dumelin, J. Scheuermann and **D. Neri** (2006) "On the magnitude of the chelate effect for the recognition of proteins by pharmacophores scaffolded by self-assembling oligonucleotides". *Chemistry and Biology*, 13, 225-231.

113 – E. Balza, L. Mortara, F. Sassi, S. Monteghirfo, B.Carnemolla, P. Castellani, **D. Neri**, R.S. Accolla, L. Zardi and L. Borsi (2006) Targeted delivery of TNFα to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histological origin. *Clin. Cancer Res.*, 12, 2575-2582.

114 – S.S. Brack, M. Silacci, M. Birchler, **D. Neri** (2006) "Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C". *Clin. Cancer Res.*, 12, 3200-3208

115 – C.E. Dumelin, J. Scheuermann, S. Melkko, **D. Neri** (2006). "Selection of streptavidin binders from a DNA-encoded chemical library". *Bioconjug Chem*. 17, 366-370.

116 – C. Rösli, G. Elia and **D. Neri** (2006) "Two-dimensional mass spectrometric mapping". *Curr. Opin. Chem. Biol*., 10, 35-41.

117 – A. Berndt, K. Anger, P. Richter, L.Borsi, S. Brack, M. Silacci, M. Franz, H. Wunderlich, M. Gajda, L. Zardi, **D. Neri**, and H. Kosmehl (2006) "Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder" *J. Cancer Res. Clin. Oncol*., 132, 537-546.

118 – A. Ettorre, C. Rösli, M. Silacci, S. Brack, G. McCombie, R. Knochenmuss, G. Elia, **D. Neri** (2006) "Recombinant antibodies for the depletion of abundant proteins from human serum" *Proteomics*, 6, 4494-4503

119 – E. Trachsel, **D. Neri** (2006) "Antibodies for angiogenesis inhibition, vascular targeting and endothelial cell transcytosis", *Adv. Drug Deliv. Rev*., 58, 735-754.

120 – C. Rösli, **D. Neri**, J. Rybak (2006) "In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature". *Nature Protocols,* 1, 192-199.

121 – J. Scheuermann, C.E. Dumelin, S. Melkko, **D. Neri** (2006) "DNA-encoded chemical libraries" *J. Biotechnol*., 126, 568-581

122 – B.M. Tijink, **D. Neri**, C.R. Leemans, M. Budde, L.M. Dinkelborg, M. Stigter-van Walsum, L. Zardi, G.A. van Dongen (2006). "Radioimmunotherapy of Head and Neck Cancer Xenografts Using 131I-Labeled Antibody L19-SIP for Selective Targeting of Tumor Vasculature. " *J. Nucl. Med*, 47, 1127-1135

123 - N. Spaeth, M.T. Wyss, J. Pahnke, G. Biollaz, E. Trachsel, K. Drandarov, V. Treyer, B. Weber, **D. Neri**, A. Buck (2006) "Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19)". *Nucl Med Biol*. 33, 661-666.

124 – V. Gafner, E. Trachsel, **D. Neri** (2006) "An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties.". *Int. J. Cancer*, 119, 2205-2212.

125 – V. Castronovo, D. Waltregny, P. Kishel, G. Elia, C. Rösli, J. Rybak, **D. Neri** (2006) "A chemical proteomic approach for the identification of accessible antigens expressed in human kidney cancer". *Mol. Cell. Proteomics*, 5, 2083-2091.

126 – M. Silacci, S.S. Brack, N. Spaeth, A. Buck,, S. Hillinger, S. Arni, W. Weder, L. Zardi, **D. Neri** (2006) "Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo." *Protein Eng Des Sel*. 19, 471-478

127 – E. Trachsel, M. Kaspar, F. Bootz, M. Detmar, **D. Neri** (2006) Selective targeting of psoriatic lesions using a human monoclonal antibody specific to oncofetal fibronectin. *J. Invest. Dermatol.*, 127, 881-886.

128 – Berndorff D, Borkowski S, Moosmayer D, Viti F, Muller-Tiemann B, Sieger S, Friebe M, Hilger CS, Zardi L, **Neri D**, Dinkelborg LM. (2006) Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. *J Nucl Med*. 47, 1707-16.

129 J. Ahlskog, G. Paganelli, **D. Neri** (2006) "Vascular tumor targeting" *Q J Nucl Med Mol Imaging*. 50, 296-309.

130 - M. T. Birchler, C. Thürl, D. Schmid, **D. Neri**, R. Waibel, A. Schubiger, S. J. Stoeckli, S. Schmid & G. W. Goerres (2007) „Immunoscintigraphy of patients with head and neck squamous cell carcinomas, with a human anti-angiogenetic antibody fragment". *Arch Otolaryngol. Head Neck Surg.*, 136, 543-548.

131 – D. Grabulovski, M. Kaspar, **D. Neri** (2007) "A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties". *J. Biol. Chem.*, 282, 3196-3204.

132 – J. Bertschinger, D. Grabulovski, **D. Neri** (2007) "Selection of single domain binding proteins by covalent DNA display". *Prot. Engin. Des. Sel.*, 20, 57-68.

133 – J. Rybak, E. Trachsel, J. Scheuermann, **D. Neri** (2007) "Ligand-based vascular targeting of disease". *Chem. Med. Chem.*, 2, 22-40.

134 - E. Trachsel, F. Bootz, M. Silacci, M. Kaspar, H. Kosmehl, **D. Neri** (2007), "Antibody-mediated delivery of interleukin-10 inhibits the progression of established collagen-induced arthritis". *Arthritis Res. Ther.* , 9, R9.

135 – V. Castronovo, P. Kischel, F. Guillonneau, L de Leval, T. Defechereux, E. De Pauw, **D. Neri**, D. Waltregny (2007) "Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method". *Proteomics*, 7, 1188-1196.

136 – T. von Lukowicz, M. Silacci, M.T. Wyss, E. Trachsel, C. Lohmann, A. Buck, T.F. Luscher, **D. Neri**, C.M. Matter (2007). "Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo". *J. Nucl. Med.*, 48, 582-587,

137 – M.T. Wyss, N. Spaeth, G. Biollaz, J. Pahnke, P. Alessi, E. Trachsel, V. Treyer, B. Weber, **D. Neri**, A. Buck (2007) "Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis". *J. Nucl. Med.*, 48, 608-614.

138 – S. Melkko, Y. Zhang, C.E. Dumelin, J. Scheuermann, **D. Neri** (2007). "Isolation of high-affinity trypsin inhibitors from a DNA-encoded chemical library" *Angew. Chem. Int. Ed. Engl*. 46, 4671-4674.

139 – M. Kaspar, E. Trachsel, **D. Neri** (2007). "The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis". *Cancer Res.*, 67, 4940-4948.

140 – E. El-Emir, J.L. Dearling, A. Huhalov, M.P. Robson, G. Boxer, **D. Neri**, G.A. van Dongen, E. Trachsel, R.H. Begent, R.B. Pedley (2007) "Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models". *Br. J. Cancer*, 96, 1862-1870.

141 – S. Melkko, C.E. Dumelin, J. Scheuermann, **D. Neri** (2007). "Lead discovery by DNA-encoded chemical libraries". *Drug Discov. Today*. 12, 465-471

142 – C. Schliemann, **D. Neri (**2007) "Antibody-based targeting of the tumor vasculature" *Biochim Biophys Acta,* 1776,175-192

143 – J.N. Rybak, C. Rösli, M. Kaspar, A. Villa, **D. Neri** (2007) "The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases". *Cancer Res.*, 67, 10948-10957.

144 – V. Lovato, C. Roesli, J. Ahlskog, J. Scheuermann, **D. Neri** (2007) "A monoclonal antibody prevents aggregation of the NBD1 domain of the cystic fibrosis transmembrane conductance regulator ".*Protein Eng Des Sel*. 20, 607-614.

145 –C. Avignolo, L. Bagnasco, B. Biasotti, A Melchiori, V. Tomati, I Bauer, A. Salis, L. Chiossone, M.C. Mingari, P. Orecchia, B. Carnemolla, **D. Neri**, L. Zardi, S. Parodi (2008) "Internalization via Antennapedia Protein Transduction Domain (PTD) of a scFv antibody toward c-Myc protein". *FASEB J.*, 22, 1237-1245.

146 – C. Roesli, V. Mumprecht, **D. Neri**, M. Detmar (2008) "Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping". *FASEB J.*, 22, 1933-1944.

147 – J. Scheuermann, C.E. Dumeli, S. Melkko, Y. Zhang, L. Mannocci, M. Jaggi, J. Sobek, **D. Neri** (2008). "DNA-encoded chemical libraries for the discovery of MMP-3 inhibitors". *Bioconj. Chem.*, 19, 778-785.

148 – A. Villa, E. Trachsel, M. Kaspar, C. Schliemann, R. Sommavilla, J.N. Rybak, C. Rösli, L. Borsi, **D. Neri** (2008) "A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo". *Int. J. Cancer*, 122, 2405-2413.

149 – C.E. Dumelin, S. Trüssel, F. Buller, E. Trachsel, F. Bootz, Y. Zhang, L. Mannocci, S.C. Beck, M. Drumea-Mirancea, M.W. Seeliger, C. Baltes, T. Müggler, F. Kranz, M. Rudin, S. Melkko, J. Scheuermann, **D. Neri** (2008) "A portable albumin binder from a DNA-encoded chemical library". *Angew. Chem. Int. Ed. Engl.*, 47, 3196-3201.

150 – C. Rösli, J.N. Rybak, **D. Neri**, G. Elia (2008) "Quantitative recovery of biotinylated proteins from streptavidin-based affinity chromatography resins". *Methods Mol. Biol.*, 418, 89-100.

151 – P. Conrotto, C. Rösli, J.N. Rybak, P. Kishel, D. Waltregny, **D. Neri***, V. Castronovo (2008) "Identification of novel tumor-associated and accessible antigens in human colon cancer by ex vivo

protein biotinylation and comparative mass spectrometry analysis". *Int. J. Cancer*, 123, 2856-2864. [* = corresponding author].

152 - F. Buller, L. Mannocci, Y. Zhang, C. Dumelin, J. Scheuermann, **D. Neri** (2008) "Design and synthesis of a novel DNA-encoded chemical library using Diels-Alder cycloadditions". *Bioorg. Med. Chem. Lett*., 18, 5926-5931.

153 – J. Mårlind, M. Kaspar, E. Trachsel, R. Sommavilla, S. Hindle, C. Bacci, L. Giovannoni, **D. Neri** (2008) "The antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy". *Clin. Cancer Res.*, 14, 6515-6524.

154 – L. Mannocci, Y. Zhang, J. Scheuermann, M. Leimbacher, G. De Bellis, E. Rizzi, C. Dumelin, S., Melkko, **D. Neri** (2008) "High-throughput sequencing allows the identification of binding molecules isolated from DNA-encoded chemical libraries". *Proc. Natl. Acad. Sci. U.S.A.*, 105, 17670-17675.

155 – M. Pedretti, A. Soltermann, S. Arni, W. Weder, **D. Neri***, S. Hillinger (2009) "Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer". *Lung Cancer*, 64, 28-33 [* = corresponding author].

156 – K. Zuberbühler, A. Palumbo, C. Bacci, L. Giovannoni, R. Sommavilla, M. Kaspar, Eveline Trachsel, **D. Neri** (2009) "A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells". *Protein Eng Des Sel*., 22, 169-174

157 – C. Schliemann, A. Palumbo, K. Zuberbuhler, A. Villa, M. Kaspar, E. Trachsel, W. Klapper, H.D. Menssen, **D. Neri** (2009) "Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2." *Blood*, 113, 2275-2283 [Cover and Editorial at pages 2121-2122].

158 – S. Sauer, P.A. Erba, M. Petrini, A. Menrad, L. Giovannoni, C. Grana, B. Hirsch, L. Zardi, G. Paganelli, G. Mariani, **D. Neri**, H. Dürkop, H.D. Menssen (2009) "Expression of the oncofetal ED-B containing fibronectin isoform in hematologic tumors enables ED-B targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients". *Blood*, 113, 2265-2274. [Cover and Editorial at pages 2121-2122].

159 – H. Kamada, T. Fugmann, **D. Neri**, C. Rösli (2009) "Improved protein sequence coverage by on resin deglycosylation and cysteine modification for biomarker discovery." *Proteomics*, 9, 783-787.

160 – B.M. Tijink, L.R. Perk, M. Budde, M.S. van Walsum, G.W.M. Visser, R.W. Klet, L.M. Dinkelborg, C.R. Leemans, **D. Neri**, G.A.M.S. van Dongen (2009) "^{124}I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of ^{131}I-L19-SIP radioimmunotherapy". *Eur. J. Nucl. Med. Mol. Imaging*, 36, 1235-1244.

161 – P. Richter, M. Tost, M. Franz, A. Altendorf-Hofmann, K. Junker, L. Borsi, **D. Neri**, H. Kosmehl, H. Wunderlich, A. Berndt (2009) "B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?" *J. Cancer Res. Clin. Oncol.*, 135, 1351-1358.

162 – C. Rösli, B. Borgia, C. Schliemann, M. Gunthert, H. Wunderli-Allenspach, R. Giavazzi, **D. Neri** (2009). "Comparative analysis of the membrane proteome of closely related metastatic and non-metastatic tumor cells". *Cancer Res.*, 69, 5406-5414.

163 – **D. Neri**, A. Brändli (2009) "Encoding Chemistry". *Nat. Chem. Biol.*, 5, 452-453.

164 – K.H. Altmann, **D. Neri**. (2009) "Next-generation therapeutics". *Curr. Opin. Chem. Biol.* 213, 231-234.

165 – J. K.J. Ahlskog, C. Schliemann, J. Mårlind, U.Qureshi, A. Ammar, R.B. Pedley, **D. Neri** (2009) "Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours". *Br. J. Cancer*, 101, 645-657.

166 – J.K.J. Ahlskog, C.E. Dumelin, S. Trüssel, J. Mårlind, **D. Neri** (2009) *In vivo* targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. *Bioorg. Med. Chem. Lett.*, 19, 4851-4856

167 – C. Schliemann, A. Wiedmer, M. Pedretti, M. Szczepanowski, W. Klapper and **D. Neri** (2009) "Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma". *Leukemia Res*., 33, 1718-1722.

168 – F. Buller, Y. Zhan, J. Scheuermann, J. Schäfer, P. Bühlmann, **D. Neri** (2009) "Discovery of TNF inhibitors from a DNA-encoded chemical library based on Diels-Alder cycloaddition". *Chemistry & Biology*, 16, 1075-1086.

169 - K. Schwager, M. Kaspar, F. Bootz, R. Marcolongo, E. Paresce, **D. Neri***, E. Trachsel. (2009) "Preclinical characterization of Dekavil (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis". *Arthritis Res. Ther.*, 11, R142. [* = corresponding author]

170 – S. Trüssel, C. Dumelin, K. Frey, A. Villa, F. Buller, **D. Neri** (2009) "New strategy for the extension of the serum half-life of antibody fragments". *Bioconj. Chem.*, 20, 2286-2292.

171 – M. Pedretti, Z. Rancic, A. Soltermann, B.A. Herzog, C. Schliemann, M. Lachat, **D. Neri**, P.A. Kaufmann (2010) "Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: three clinical-grade fully human antibodies. *Atherosclerosis*, 208, 382-389.

172 – C. Schliemann, C. Rösli, H. Kamada, B. Borgia, T. Fugmann, W. Klapper, **D. Neri** (2010) "*In vivo* biotinylation of the vasculature in B-cell lymphoma identifies Bst-2 as a target for antibody-based therapy" *Blood*, 115, 736-744

173 – B. Borgia, C. Rösli, T. Fugmann, **D. Neri*,** R. Giavazzi (2010) "Accessible markers of liver metastasis revealed by mass spectrometric analysis of vascular structures biotinylated by perfusion of tumor-bearing mice" *Cancer Res.*, 70, 309-318 [* = corresponding author].

174 – S. Pfaffen, T. Hemmerle, M. Weber, **D. Neri** (2010) "Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3" *Exp. Cell Res.*, 316, 836-847.

175 – F. Schwarz, W. Huang, C. Li, B.L. Schulz, C. Lizak, A. Palumbo, S.Numao, **D. Neri**, M. Aebi, L.X. Wang (2010) "A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation ". *Nat. Chem. Biol.*, 6, 264-266.

176 – C. Schliemann, **D. Neri** (2010)"Antibody-based vascular tumor targeting". *Recent Results Cancer Res.*, 180, 201-216.

177 – D. Sgier, K. Zuberbühler, S. Pfaffen, **D. Neri** (2010) "Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA". *Protein Eng. Des. Sel.*, 23, 261-269.

178 – C.M. Alonso, A. Palumbo, A.J. Bullous, F. Pretto, **D. Neri**, R.W. Boyle (2010) "Site-specific and stoichiometric conjugation of cationic porphyrins to antiangiogenic monoclonal antibodies". *Bioconj. Chem.*, 21, 302-313.

179 – R. Sommavilla, V. Lovato, A. Villa, D. Sgier, **D. Neri** (2010) "Design and construction of a naïve mouse antibody phage display library". *J. Immunol. Methods*, 353, 31-43.

180 – S. Pfaffen, K. Frey, I. Stutz, C. Rösli, **D. Neri** (2010) "Tumor targeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3". *Eur. J. Nucl. Med. Mol. Imaging*, 37, 1559-1565.

181 – A. Berndt, R. Köllner, P. Richter, M. Franz, A. Voigt, A. Berndt, L. Borsi, R. Giavazzi, **D. Neri**, H.Kosmehl (2010) "A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies". *Histochem. Cell Biol.*, 133, 467-475.

182 – M. Franz, B.R. Brehm, P. Richter, K. Gruen, **D. Neri**, H. Kosmehl, K. Hekmat, A. Renner, J. Gummert, H.R. Figulla, A. Berndt (2010) "Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies". *J. Mol. Histol.,* 41, 39-50.

183 – J. Scheuermann, **D. Neri** (2010) "DNA-encoded chemical libraries: a tool for Drug Discovery and for Chemical Biology", *ChemBioChem*, 11, 931-937.

184 – S. Melkko, L. Mannocci, C. Dumelin, A. Villa, R. Sommavilla, Y. Zhang, M. Grütter, N. Keller, L. Jermutus, R. Jackson, J. Scheuermann, **D. Neri** (2010). "Isolation of a small molecule inhibitor of the anti-apoptotic protein Bcl-xL from a DNA-encoded chemical library". *ChemMedChem*, 5, 584-590.

185- T. Fugmann, **D. Neri***, C. Rösli, (2010) Deep-QuanTR: MALDI-MS-based label free quantification of proteins in complex biological samples. *Proteomics*, 10, 2631-2643 [* = corresponding author].

186 – R. Sommavilla, N. Pasche, E. Trachsel, L. Giovannoni, C. Roesli, A. Villa, **D. Neri***, M. Kaspar (2010). "Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12". *Protein Eng. Des. Sel.*, 23, 653-661. [* = corresponding author].

187 – F. Buller, L. Mannocci, J. Scheuermann, **D. Neri** (2010) "Drug discovery with DNA-encoded chemical libraries". *Bioconj. Chem.*, 21, 1571-1580.

188 – F. Buller, M. Steiner, J. Scheuermann, L. Mannocci, I. Nissen, M. Kohler, C. Beisel, **D. Neri**. (2010). "High throughput sequencing for the identification of binding molecules from DNA-encoded chemical libraries". *Bioorg. Med. Chem. Lett.*, 20, 4188-4192.

189 – C. Rösli, **D. Neri** (2010) "Methods for the identification of vascular markers in health and disease: from the bench to the clinic". *J. Proteomics*, 73, 2219-2229.

190 – V. Strassberger, T. Fugmann, **D. Neri**, C. Roesli (2010). "Chemical proteomics and bioinformatic strategies for the identification and quantification of vascular antigens in cancer". *J. Proteomics*, 73, 1954-1973.

191 – K. Frey, C. Schliemann, K. Schwager, R. Giavazzi, M. Johannsen, **D. Neri** (2010). "The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma". *J. Urol.*, 184, 2540-2548.

192 – M. Johannsen, G. Spitaleri, G. Curigliano, J. Roigas, S. Weikert, C. Kempfkensteffen, A. Roemer, C. Kloeters, P. Rogalla, G. Pecher, K. Miller, A. Berndt, H. Kosmehl, E. Trachsel, M. Kaspar, V. Lovato, R. Gonzalez-Iglesias, L. Giovannoni, H.D. Menssen, **D. Neri***, F. De Braud. (2010). "The tumor targeting L19-L2 immunocytokine: preclinical safety studies, Phase I clinical trial in patients with solid tumors and expansion into patients with advanced renal cell carcinoma". *Eur. J. Cancer*, 46, 2926-2935 [* = corresponding author].

193 – M. Pedretti, C. Verpelli, J. Mårlind, G. Bertani, C. Sala, **D. Neri***, L. Bello (2010) "Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma". *Br. J. Cancer*, 103, 827-836 [* = corresponding author].

194 – M. Rinderknecht, A. Villa, K. Ballmer-Hofer, **D. Neri**, M. Detmar (2010). "Phage-derived full human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3. *PLoS One*, 5, e11941.

195 – V. Strassberger, S. Trüssel, T. Fugmann, **D. Neri**, C. Roesli (2010). "A novel reactive ester derivative of biotin with reduced membrane permeability for *in vivo* biotinylation experiments". *Proteomics*, 10, 3544-3548.

196 – L. Mannocci, S. Melkko, F. Buller, I. Molnar, G. Bianke, C. E. Dumelin, J. Scheuermann, **D. Neri** (2010) "Isolation of potent and specific trypsin inhibitors from a DNA-encoded chemical library". *Bioconj. Chem.*, 21, 1836-1841.

197 – V. Mumprecht, M. Honer, B. Vigl, S.T. Proulx, E. Trachsel, M. Kaspar, N.E. Banziger-Tobler, R. Schibli, **D. Neri**, M. Detmar (2010) "In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography" *Cancer*

Res., 70, 8842-8851

198 – M. Franz, K. Grün, P. Richter, B.R. Brehm, M. Fritzenwanger, K. Hekmat, **D. Neri**, Gummert, H.R. Figulla, H. Kosmehl, A. Berndt, A. Renner (2010) "Extracellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A(+) fibronectin, alpha-smooth muscle actin and B (+) tenascin-C in chronic cardiac allograft rejection." *Histochem. Cell Biol.*, 134, 503-517

199 – M. Franz, A. Berndt, K. Grün, P. Richter, H. Kosmehl, **D. Neri**, J. Gummert, H.R. Figulla, B.R. Brehm, A. Renner (2010) "Expression of extra domain A containing fibronectin in chronic cardiac allograft rejection." *J. Heart Lung Transpl.*, 30, 86-94

200 – F. Buller, M. Steiner, K. Frey, D. Mircsof, J. Scheuermann, M. Kalisch, P. Bühlmann, C.T. Supuran, **D. Neri** (2011) "Selection of carbonic anhydrase IX inhibitors from one million DNA-encoded compounds". *ACS Chemical Biol.*, 6, 336-344.

201 – M. Fiechter, K. Frey, T. Fugmann, P.A. Kaufmann, **D. Neri**. (2011) "Comparative *in vivo* analysis of the atherosclerotic plaque targeting properties of eight human monoclonal antibodies". *Atherosclerosis*, 214, 325-330.

201 – A. Baldinger, B.R. Brehm, P. Richter, T. Bossert, K. Gruen, K. Hekmat, H. Kosmehl, **D. Neri**, H.R. Figulla, A. Berndt, M. Franz (2011) "Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis". *Histochem. Cell. Biol.*, 135, 427-441.

202 – K. Frey, A. Zivanovic, K. Schwager, **D. Neri** (2011) "Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation". *Integr. Biol.*, 3, 468-478.

203 – C. Roesli, T. Fugmann, B. Borgia, C. Schliemann, **D. Neri**, M. Jucker (2011) "The accessible cerebral vascular proteome in a mouse model of cerebral beta-amyloidosis". *J. Proteomics*, 74, 539-546.

204 – T. Fugmann, B. Borgia, C. Révész, M. Godó, C. Forsblom, P. Hamar, H. Holtöfer, **D. Neri**, C. Roesli (2011) "Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy" *Kidney Int.*, 80, 272-281.

205 – K. Frey, M. Fiechter, K. Schwager, B. Belloni, M. Barysch, **D. Neri**, R. Dummer (2011) "Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions". *Exp. Dermatol.*, 20, 685-688.

206 – M. Czabanka, G. Parmaksiz, S.H. Bayerl, M. Nieminen, E. Trachsel, H.D. Menssen, R. Erber, **D. Neri**, P. Vajkoczy (2011) "Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies". *Eur. J. Cancer*, 47, 1276-1284.

207 – A. Palumbo, F. Hauler, P. Dziunycz, K. Schwager, A. Soltermann, F. Pretto, C. Alonso, G.F. Hofbauer, R.W. Boyle, **D. Neri** (2011) "A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels". *Br. J. Cancer*, 104, 1106-1115.

208 – A. Villa, V. Lovato, E. Bujak, S. Wulhfard, N. Pasche, **D. Neri** (2011) "A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin". *MAbs*, 3, 264-272.

209 – N. Pasche, J. Woytschak, K. Frey, S. Wulhfard, A. Villa, **D. Neri** (2011) "Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7". *J. Biotechnol.*, 154, 84-92.

210 – M. Steiner and **D. Neri** (2011) "Antibody-radionuclide conjugates for cancer therapy: historical perspectives and new trends". *Clin. Cancer Res.*, 17, 6406-6416.

211 – **D. Neri** and C. Supuran (2011) "New drugs interfering with pH regulation in tumors". *Nature Rev. Drug Discov.*, 10, 767-777.

212 – K. Schwager, A. Villa, C. Rösli, **D. Neri**, M. Rösli-Khabas, G. Moser (2011) "A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer". *Head Neck Oncol*., 3, 25

213 – K. Schwager, F. Bootz, P. Imesch, M. Kaspar, E. Trachsel, **D. Neri** (2011) "The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model". *Hum. Reprod.*, 26, 2344-2352.

214 – T. Gecks, K. Junker, M. Franz, P. Richter, M. Walther, Voigt, **D. Neri**, H. Kosmehl, H. Wunderlich, M. Kiehntopf, A. Berndt (2011) "B domain containing Tenascin-C: a new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder?" *Clin. Chim. Acta*., 412, 1931-1936.

215 – T.K. Eigentler, B. Weide, F. de Braud, G. Spitaleri, A. Romanini, A. Pflugfelder, R. Gonzales-Iglesias , A. Tasciotti, L. Giovannoni, K. Schwager, V. Lovato, M. Kaspar, E. Trachsel, H.D. Menssen, **D. Neri**, C. Garbe (2011) "A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma." *Clin. Cancer Res.*, 17, 7732-7742

216 – L. Mannocci, M. Leimbacher, M. Wichert, J. Scheuermann, **D. Neri** (2011) "20 years of DNA-encoded chemical libraries". *Chem. Comm.*, 47, 12747-12753.

217 – N. Pasche, K.D. Frey, **D. Neri** (2012) "The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate". *Angiogenesis*,15, 165-169.

218 – K. Galler, K. Junker, M. Franz, J. Hentschel, P. Richter, M. Gajda, A. Göhlert, F. von Eggeling, R. Heller, R. Giavazzi, **D. Neri**, H. Kosmehl, H. Wunderlich, A. Berndt (2012) "Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery." *Histochem. Cell Biol.*, 137, 195-204.

219 – M. Franz, **D. Neri**, A. Berndt (2012) "Chronic cardiac allograft rejection: critical role of ED-A(+) fibronectin and implications for targeted therapy strategies." *J. Pathol.*, 226, 557-561.

220 – G.J. Bernardes, G. Casi, S. Trüssel, I. Hartmann, K. Schwager, J. Scheuermann, **D. Neri** (2012) "A traceless vascular-targeting antibody-drug conjugate for cancer therapy". *Angew. Chemie Int. Ed. Engl.*, 51, 941-944.

221 – N. Pasche, **D. Neri** (2012) "Immunocytokines: a novel class of potent armed antibodies". *Drug Discov. Today*, 17, 583-590.

222 – G. Casi, **D. Neri** (2012) "Antibody-drug conjugates: basic concepts, examples and future perspectives". *J. Control. Release*, 161, 422-428.

223 – S. Trüssel, J. Scheuermann, **D. Neri** (2012) "Half-life extension by binding to albumin through small molecules". From *Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives*, First Edition, Ed. Roland Kontermann, Wiley-VCH Verlag GmbH & Co, KGaA; pages 285-296.

224 – A. Cyranka-Csaja, S. Wulhfard, **D. Neri,** J. Otlewski, (2012) "Selection and characterization of human antibody fragments specific for psoriasin – a cancer associated protein". *Biochem. Biophys. Res. Commun.*, 419, 250-255.

225 – M. Moschetta, F. Pretto, A. Berndt, K. Galler, P. Richter, A. Bassi, P. Oliva, E. Micotti, G. Valbusa, K. Schwager, M. Kaspar, E. Trachsel, H. Kosmehl, M.R. Bani, **D. Neri**, R. Giavazzi (2012) "Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-positive metastatic human melanoma xenografts". *Cancer Res.*, 72, 1814-1824.

226 – G. Casi, N. Huguenin-Dezot, K. Zuberbühler, J. Scheuermann, **D. Neri** (2012). "Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery". *J. Am. Chem. Soc.*, 134, 5887-5892.

227 – P.A. Erba, M. Sollini, E. Orciuolo, C. Traino, M. Petrini, G. Paganelli, E. Bombardieri, C. Grana, L. Giovannoni, **D. Neri**, H.D. Menssen, G. Mariani (2012) "Radioimmunotherapy with Radretumab in patients with relapsed hematologic malignancies". *J. Nucl. Med.,* 53, 922-927.

228 – M. Leimbacher, Y. Zhang, L. Mannocci, M. Stravs, T. Geppert, J. Scheuermann, G. Schneider, **D. Neri** (2012) "Discovery of small molecule interleukin-2 inhibitors from a DNA-encoded chemical library". *Chemistry*, 18, 7729-7737.

229 – F. Papadia, V. Basso, R. Patuzzo, A. Maurichi, A. Di Florio, L. Zardi, E. Ventura, R. González-Iglesias, V. Lovato, L. Giovannoni, A. Tasciotti, **D. Neri**, M. Santinami, H.D. Menssen, F. De Cian (2013)" Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma". *J. Surg. Oncol.*, 107, 173-179.

230 – K. Gutbrodt, **D. Neri** (2012) "Immunocytokines". *Antibodies*, 1, 70-87.

231 - K. Zuberbühler, G. Casi, G.J. Bernardes, **D. Neri** (2012) "Fucose-specific conjugation of hydrazide derivatives to a vascular targeting antibody in IgG format". *Chem. Commun.*, 48, 7100-7102.

232 – N. Pasche, S. Wulhfard, F. Pretto, E. Carugati, **D. Neri** (2012) "The antibody-based delivery of interleukin-12 to the tumor neo-vasculature eradicates cancer in combination with paclitaxel". *Clin. Cancer Res.*, 18, 4092-4103.

233 – T. Hemmerle, S. Wulhfard, **D. Neri** (2012) "A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data". *Protein Eng. Des. Sel.*, 25, 851-854.

234 – T. List, **D. Neri** (2012) "Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site". *MAbs*, 4, 775-783.

235 – K. Schwager, T. Hemmerle, D. Aebischer, **D. Neri** (2013) "The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or L19-TNF". *J. Invest. Dermatol.*, 133, 751-758.
[Commentary in the same issue of *J. Invest. Dermatol.* by Tao Wang, Rajasekharan Somasundaram and Meenhard Herlyn, page 595-596].

236 – D.A. Heuveling, R. de Bree, D.J. Vugts, M.C. Huisman, L. Giovannoni, O.S. Hoekstra, C.R. Leemans, **D. Neri**, G.A. van Dongen (2013) "Phase 0 Microdosing PET Study Using the Human Mini Antibody F16SIP in Head and Neck Cancer Patients.". *J. Nucl. Med.*, 54, 397-401.

237 – M. Steiner, K.L. Gutbrodt, **D. Neri** (2013) "Tumor-targeting antibody-anticalin fusion proteins for *in vivo* pretargeting applications". *Bioconj. Chem*., 24, 234-241.

238 – G. Spitaleri, R. Berardi, C. Pierantoni, T. De Pas, C. Noberasco, C. Libbra, R. González-Iglesias, L. Giovannoni, A. Tasciotti, **D. Neri**, H.D. Menssen, F. de Braud (2013) "Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours.". *J. Cancer Res. Clin. Oncol.*, 139, 447-455.

239 – M. Franz, I. Hilger, K. Grün, S. Kossatz, P. Richter, I. Petersen, C. Jung, J. Gummert, H.R. Figula, H. Kosmehl, **D. Neri**, A. Berndt, A. Renner (2013) "Selective imaging of chronic cardiac rejection using a human antibody specific to the alternatively spliced EDA domain of fibronectin." *J. Heart Lung Transpl.*, 32, 641-650.

240 – T. List , **D. Neri** (2013) "Immunocytokines: a review of molecules in clinical development for cancer therapy". *Clin. Pharmacol.*, 5, 29-45.

241 – M. Franz, A. Berndt, **D. Neri**, K. Galler, K. Grün, C. Porrmann, F. Reinbothe, G. Mall, P. Schlattmann, A. Renner, H.R. Figulla, C. Jung, F. Küthe (2013) "Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B(+) tenascin-C and ED-A(+) fibronectin in dilated cardiomyopathy: Potential impact on disease progression and patients' prognosis." *Int. J. Cardiol.*, 168, 5344-5351

242 - G.L. Poli, C. Bianchi, G. Virotta, A. Bettini, R. Moretti, E. Trachsel, G. Elia, L. Giovannoni, **D. Neri**, A. Bruno (2013) "Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study". *Cancer Immunol. Res.*, 1, 134-143 (2013).

243 – F. Pretto, **D. Neri** (2013) "Pharmacotherapy of metastatic melanoma: emerging trends and opportunities for a cure". *Pharmacol. Ther.*, 139, 405-411.

244 – N. Krall, J. Scheuermann, **D. Neri** (2013) "Small Targeted Cytotoxics: Current State and Promises from DNA Encoded Chemical Libraries". *Angew. Chemie Int. Ed. Engl.*, 52, 1384-1402

245 – T. Hemmerle, P. Probst, L. Giovannoni, A.J. Green, T. Meyer, **D. Neri** (2013) "The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity". *Br. J. Cancer*, 109, 1206-1213.

246 – K.L. Gutbrodt, C. Schliemann, L. Giovannoni, K. Frey, T. Pabst, W. Klapper, W.E. Berdel, **D. Neri** (2013). "Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia". *Science Transl. Med.*, 5, 201ra118.

247 – G.J. Bernardes, M. Steiner, I. Hartmann, **D. Neri***, G. Casi (2013). "Site-specific chemical modification of antibody fragments using traceless cleavable linkers". *Nature Protoc.*, 8, 2079-2089 [* = corresponding author].

248 – F. Doll, K. Schwager, T. Hemmerle, **D. Neri** (2013) "Murine analogues of etanercept and F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse". *Arthritis Res. Ther.*, 15, R138.

249 – **D. Neri** (2013) "Antibody drug conjugates for cancer therapy". *Nature Biotechnol*., [www.nature.com/nbt/extra/adc/pdf/adc_poster.pdf]

250 – M. Steiner, I. Hartmann, E. Perrino, G. Casi, S. Brighton, I. Jelesarov, G. J. L. Bernardes, **D. Neri** (2013) "Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature". *Chem. Sci.*, 4, 297-302.

251 - J. Scheuermann and **D. Neri** (2014) "Dual pharmacophore DNA-encoded chemical libraries". *A Handbook for DNA-Encoded Chemistry*, pages 349-356. Edited by Robert A. Goodnow, Jr., John Wiley & Sons, Hoboken (New Jersey).

252 - R. Locher, P.A. Erba, B. Hirsch, E. Bombardieri, L. Giovannoni, **D. Neri**, H. Dürkop, H.D. Menssen (2014). "Abundant *in vitro* expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of ^{131}I-L19SIP in a prostate cancer patient". *J. Cancer Res. Clin. Oncol.*, 140, 35-43

253 – T. Hemmerle, **D. Neri** (2014) "The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neo-vasculature eradicates tumors in three mouse models of cancer". *Int. J. Cancer*, 134, 467-477.

254 – N. Ravenni, M. Weber, **D. Neri** (2014) "A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer". *MAbs*, 6, 86-94.

255 – L. Aloj, L. D'Ambrosio, M. Aurilio, A. Morisco, F. Frigeri, C. Caraco', F. Di Gennaro, G. Capobianco, L. Giovannoni, H.D. Menssen, **D. Neri**, A. Pinto, S. Lastoria (2014) "Radioimmunotherapy with Tenarad, a ^{131}I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's Lymphoma". *Eur. J. Nucl. Med. Mol. Imaging*, 41, 867-877.

256 – N. Krall, F. Pretto, W. Decurtins, G.J.L. Bernardes, C. Supuran, **D. Neri** (2014) "A small molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors". *Angew. Chemie Int. Ed. Engl.*, 53, 4321-4325.

257 – T. Hemmerle, **D. Neri** (2014) "The dose dependent tumor targeting of antibody-interferon gamma fusion proteins reveals an unexpected receptor trapping mechanism *in vivo*". *Cancer Immunol. Res.*, 2, 559-567.

258 – E. Perrino, M. Steiner, N. Krall, G.J. Bernardes, F. Pretto, G. Casi, **D. Neri** (2014) "Curative properties of non-internalizing antibody-drug conjugates based on maytansinoids". *Cancer Res.*, 74, 2569-2578.

259 – E. Bujak, M. Matasci, **D. Neri**, S. Wulhfard (2014) "Reformatting of scFv antibodies into the scFv-Fc format and their purification". *Methods Mol. Biol.*, 1131, 315-334.

260 – V. Strassberger, K.L. Gutbrodt, N. Krall, C. Roesli, H. Takizawa, Manz, M.G., Fugmann T., **D. Neri** (2014) "A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development". *J. Proteomics*, 99, 138-151.

261 – T. Hemmerle, C. Hess, D. Venetz, **D. Neri** (2014) "Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis factor superfamily". *J. Biotechnol.*, 172, 73-76.

262 – C. Hess, D. Venetz, **D. Neri** (2014) "Emerging classes of armed antibody therapeutics against cancer". *Med. Chem. Comm.*, 5, 408-431.

263 – R. Franzini, **D. Neri***, J. Scheuermann (2014) "DNA-encoded chemical libraries: advancing beyond conventional small-molecule libraries". *Acc. Chem. Res.*, 47, 1247-1255 [* = corresponding author; Editor's Choice]

264 – G. Elia, T. Fugmann, **D. Neri** (2014) "From target discovery to clinical trials with armed antibody products". *J. Proteomics*, 107, 50-55.

265 – B. Weide, T.K. Eigentler, A. Pflugfelder, H. Zelba, A. Martens, G. Pawelec, L. Giovannoni, P.A. Ruffini, G. Elia, **D. Neri**, R. Gutzmer, J.C. Becker, C. Garbe (2014) "Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.". *Cancer Immunol. Res.*, 2, 668-678.

266 – T. Hemmerle, F. Doll, **D. Neri** (2014) "The antibody-based delivery of IL4 to the neo-vasculature cures mice with arthritis". *Proc. Natl. Acad. Sci. U.S.A.*, 111, 12008-12012

267 – K.L. Gutbrodt, G. Casi, **D. Neri** (2014) "Antibody-based delivery of interleukin-2 and cytotoxics eradicates tumors in immunocompetent mice". *Mol. Cancer Ther.*, 13, 1772-1776

268 - S. Botter, **D. Neri**, B. Fuchs (2014) "Recent advances in osteosarcoma". *Curr. Opin. Pharmacol.*, 16, 15-23.

269 – M. Franz, M. Matusiak-Brückner, P. Richter, K. Grün, B. Ziffels, **D. Neri**, H. Maschek, U. Schulz, A. Pfeil, C. Jung, H.R. Figulla, J. Gummert, A. Berndt, A. Renner (2014) "De novo

expression of fetal ED-A+fibronectin and B+tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.". *J. Mol. Histol.*, 45, 519-532.

270 – C. Hess, **D. Neri** (2014) "Tumor targeting properties of novel immunocytokines based on murine IL1β and IL6". *Protein Eng. Des. Sel.*, 27, 207-213.

271 – C. Hess, **D. Neri** (2014) "Evaluation of antibody-chemokine fusion proteins for tumor targeting applications". *Exp. Biol. Med.*, 239, 842-852.

272 – F. Pretto, N. Castioni, G. Elia, **D. Neri** (2014) "Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy". *Cancer Immunol. Immunother.*, 63, 901-910.

273 – E. Bujak, F. Pretto, D. Ritz, L. Gualandi, S. Wulhfard, **D. Neri** (2014) "Monoclonal antibodies to murine thrombospondin-1 and thrombospondin-2 reveal differential expression patterns in cancer and low antigen expression in normal tissues.". *Exp. Cell Res.*, 327, 135-145.

274 – M. Weber, E. Bujak, A. Putelli, A. Villa, M. Matasci, L. Gualandi, T. Hemmerle, S. Wulhfard, **D. Neri** (2014) "A Highly Functional Synthetic Phage Display Library Containing over 40 Billion Human Antibody Clones". *PLOS One*, 9, e100000.

275 – N. Krall, F. Pretto, **D. Neri** (2014) "A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumor regression in mice". *Chem. Sci.*, 5, 3640-3644.

276 – B. Weide, T.K. Eigentler, G. Elia, **D. Neri**, C. Garbe (2014) "Limited efficacy of intratumoral IL-2 applied to large melanoma metastases". *Cancer Immunol. Immunother.*, 63, 1231-1232.

277 – R.M. Franzini, F. Samain, M. Abd El Rahman, G. Mikutis, A. Nauer, M. Zimmermann, J. Scheuermann, J. Hall, **D. Neri** (2014) "Systematic evaluation and optimization of modification reactions of oligonucleotides with amines and carboxylic acids for the synthesis of DNA-encoded chemical libraries". *Bioconj. Chem.*, 25, 1453-1461.

278 – A. Putelli, J.D. Kiefer, M. Zadory, M. Matasci, **D. Neri** (2014) "A fibrin-specific monoclonal antibody from a designed phage display library inhibits clot formation and localizes to tumors *in vivo*". *J. Mol. Biol.*, 426, 3606-3618

279 – T. Hemmerle, S. Zgraggen, M. Matasci, C. Halin, M. Detmar, **D. Neri** (2014) "Antibody-mediated delivery of interleukin-4 to the neovasculature reduces chronic skin inflammation". *J. Dermatol. Sci.*, 76, 96-103.

280 – T. List, G. Casi, **D. Neri** (2014) "A chemically-defined trifunctional antibody-cytokine-drug conjugate with potent anti-tumor activity". *Mol. Cancer Ther.*, 13, 2641-2652

281 – M. Wichert, N. Krall, W. Decurtins, R.M. Franzini, F. Pretto, P. Schneider, **D. Neri***, J. Scheuermann (2015) "Dual-pharmacophore small molecule display facilitates *de novo* ligand discovery and affinity maturation". *Nat. Chem.*, 7, 241-249 [* = corresponding author].

282 – R. Danielli, R. Patuzzo, P.A. Ruffini, A. Maurichi, L. Giovannoni, G. Elia, **D. Neri**, M. Santinami (2015) "Armed antibodies for cancer treatment: a promising tool in a changing era". *Cancer Immunol. Immunother.*, 64, 113-121.

283 – C.M. Zegers, N.H. Rekers, D.H. Quaden, N.G. Lieuwes, A. Yaromina, W.T. Germeraad, L. Wieten, E.A. Biessen, L. Boon, **D. Neri**, E.G. Troost, L.J. Dubois, P. Lambin (2015) "Radiotherapy combined with the immunocytokine (L19-IL2) provides long-lasting anti-tumor effects". *Clin. Cancer Res.*, 21, 1151-1160.

284 – C. Catania, M. Maur, R. Berardi, A. Rocca, A.M. Di Giacomo, G. Spitaleri, C. Masini, C. Pierantoni, R. González-Iglesias, G. Zigon, A. Tasciotti, L. Giovannoni, V. Lovato, G. Elia, H.D. Menssen, **D. Neri**, S. Cascinu, P.F. Conte, F. de Braud (2015) "The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumours and expansion into patients with metastatic breast cancer". *Cell Adhes. Migr.*, 9, 14-21.

285 – S. Wieckowski, T. Hemmerle, S.S. Prince, B.D. Schlienger, S. Hillinger, **D. Neri**, A. Zippelius (2015) "Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma". *Lung Cancer*, 88, 9-15.

286 – R.M. Franzini, T. Ekblad, N. Zhong, M. Wichert, W. Decurtins, A. Nauer, M.Zimmermann, F. Samain, J. Scheuermann, P.J. Brown, J. Hall, S. Gräslund, H. Schüler, **D. Neri** (2015) "Identification of structure-activity relationships from screening a structurally compact DNA-encoded chemical library". *Angew. Chemie Int. Ed. Engl.*, 54, 3927-3931.

287 – D. Venetz, C. Hess, C. Lin, M. Aebi, **D. Neri** (2015) "Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies". *Proc. Natl. Acad. Sci. U.S.A.*, 112, 2000-2005.

288 – C. Hess, **D. Neri** (2015) "The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity". *Cancer Immunol. Immunother.*, 64, 635-644.

289 – G. Casi, **D. Neri** (2015) "Non-internalizing targeted cytotoxics for cancer therapy". *Mol. Pharm.*, 12, 1880-1884.

290 – J. Scheuermann, **D. Neri** (2015) "Dual-pharmacophore DNA-encoded chemical libraries". *Curr. Opin. Chem. Biol.*, 26, 99-103.

291 – R.M. Franzini, A. Nauer, J. Scheuermann, **D. Neri** (2015) "Interrogating target-specificity by parallel screening of a DNA-encoded chemical library against closely related proteins". *Chem. Commun.*, 51, 8014-8016.

292 – C. Schliemann, K.L. Gutbrodt, A. Kerkhoff, M. Pohlen, S. Wiebe, G. Silling, L. Angenendt, T. Kessler, R.M. Mesters, L. Giovannoni, M. Schaefers, B. Altvater, C. Rossig, I. Gruenewald, E. Wardelmann, G. Koehler, **D. Neri**, M. Stelljes, W.E. Berdel (2015) "Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. *Cancer Immunol. Res.*, 3, 547-556.

293 – F. Quattrone, A.M. Sanchez, M. Pannese, T. Hemmerle, P. Vigano', M. Candiani, F.

Petraglia, **D. Neri**, P. Panina-Bordignon (2015). "The targeted delivery of interleukin-4 inhibits development of endometriotic lesions in a mouse model". *Reprod. Sci.*, 22, 1143-1152.

294 – T. Dietrich, D. Berndorff, T. Heinrich, T. Hucko, E. Stepina, P. Hauff, L.M. Dinkelborg, K. Atrott, L. Giovannoni, **D. Neri**, E. Fleck, K. Graf, H.D. Menssen (2015). "Targeted ED-B fibronectin SPECT in vivo imaging in experimental atherosclerosis". *Q. J. Nucl. Med. Mol. Imaging*, 59, 228-237.

295 – J. Scheuermann & **D. Neri** (2015) "Next generation therapeutics: creating and exploiting the chemistry of large numbers". *Curr. Opin. Chem. Biol.*, 26, iv-v.

296 – N. Börschel, C. Schwöppe, C. Zerbst, L. Angenendt, T. Kessler, W. Klapper, L. Giovannoni, G. Elia, **D. Neri**, W.E. Berde, R.M. Mesters, C. Schliemann (2015). "Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature". *Leuk. Res.*, 39, 739-748.

297 – R. Danielli, R. Patuzzo, A.M. Di Giacomo, G. Gallino, A. Maurichi, A. Di Florio, O. Cutaia, A. Lazzeri, C. Fazio, C. Miracco, L. Giovannoni, G. Elia, **D. Neri**, M. Maio, M. Santinami (2015) "Intralesional administration of L19-IL2/L19-TNF in Stage III or Stage IVM1a melanoma patients: results of a phase II study". *Cancer Immunol. Immunother.*, 64, 999-1009.

298 – E. Bujak, F. Pretto, **D. Neri** (2015) "Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids". *Invest. New Drugs,* 33, 791-800.

299 – F. Bootz, A.S. Schmid, **D. Neri** (2015) "Alternatively spliced EDA domain of fibronectin is a target for pharmacodelivery applications in inflammatory bowel disease". *Inflamm. Bowel Dis.*, 21, 1908-1917.

300 – **D. Neri** (2015) "Imaging T cells *in vivo*". *J. Nucl. Med.*, 56, 1135-1136.

301 – M. Fran, F. Doll, K. Grün, P. Richter, N. Köse, B. Ziffels, H. Schubert, H.R. Figulla, C. Jung, J. Gummert, A. Renner, **D. Neri**, A. Berndt (2015) "Targeted delivery of interleukin-10 to chronic cardiac allograft rejection using a human monoclonal antibody specific to the extra-domain A fibronectin". *Int. J. Cardiol.*, 195, 311-322.

302 – F. Samain, T. Ekblad, G. Mikutis, N. Zhong, M. Zimmermann, A. Nauer, D. Bajic, W. Decurtins, J. Scheuermann, P.J. Brown, J. Hall, S. Gräslund, H. Schüler, **D. Neri***, R.M. Franzini (2015) "Tankyrase 1 inhibitors with drug-like properties identified by screening a DNA-encoded chemical library" *J. Med. Chem.*, 58, 5143-5149 [* = corresponding author].

303 – G. Casi & **D. Neri** (2015) "Antibody-drug conjugates and small molecule-drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents". *J. Med. Chem.*, 58, 8751-8761.

304 – R.M. Franzini, S. Biendl, G. Mikutis, F. Samain, J. Scheuermann, **D. Neri** (2015) "Cap-and-catch purification for enhancing the quality of libraries of DNA conjugates". *ACS Comb. Sci.,* 17, 393-398.

305 – N.H. Rekers, C.M. Zegers, A. Yaromina, N.G. Lieuwes, R. Biemans, B.L. Senden-

Gijsbers, M. Losen, E.J. Van Limbergen, W.T. Germeraad, **D. Neri**, L. Dubois, P. Lambin (2015) "Combination of radiotherapy and the immunocytokine L19-IL2: additive effects in a NK cell dependent tumour model". *Radiother. Oncol.*, 116, 438-442.

306 – R. Gébleux, S. Wulhfard, G. Casi, **D. Neri** (2015). "Antibody format and drug release rate determine the therapeutic activity of non-internalizing antibody-drug conjugates". *Mol. Cancer Ther.*, 14, 2606-2612.

307 – A. Sofron, D. Ritz, **D. Neri**, T. Fugmann (2016). "High-resolution analysis of the murine MHC class II peptidome". *Eur. J. Immunol.*, 46, 319-328.

308 – F. Bootz, **D. Neri** (2016) "Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions". *Drug Discov. Today*, 21, 180-189.

309 – J.D. Kiefer & **D. Neri** (2016) "Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site". *Immunol. Rev.*, 270, 178-192.

310 – N. Krall, F. Pretto, M. Mattarella, C. Müller, **D. Neri** (2016) "A technetium-99m ligand of carbonic anhydrase IX selectively targets renal cell carcinoma *in vivo*". *J. Nucl. Med.*, 57, 943-949.

311 – J.Z. Kawalkowska, T. Hemmerle, F. Pretto, M. Matasci, **D. Neri**, R.O. Williams (2016) "Targeted IL-4 therapy synergizes with dexamethasone to induce a state of tolerance by promoting Treg cells and macrophages in mice with arthritis.". *Eur. J. Immunol.*, 46, 1246-1257.

312 – T.P. Schmidt, A.M. Perna, T. Fugmann, M. Böhm, J. Hiss, S. Haller, C. Götz, N. Tegtmeyer, B. Hoy, T.T. Rau, **D. Neri**, S. Backert, G. Schneider, S. Wessler (2016) "Identification of E-cadherin signature motifs functioning as cleavage sites for *Helicobacter pilori* HtrA". *Sci. Rep.*, 6:23264.

313 – W. Decurtins, M. Wichert, R.M. Franzini, F. Buller, M.A. Stravs, Y. Zhang, **D. Neri**, J. Scheuermann (2016) "Automated screening for small organic ligands using DNA-encoded chemical libraries". *Nat. Protocols*, 11, 764-780.

314 – D. Ritz , A. Gloger, B. Weide , C. Garbe , **D**. **Neri***, T. Fugmann. (2016) "High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera". *Proteomics*, 16, 1570-1580 [*) Corresponding author; Cover dedicated to the article].

315 – **D. Neri** & P.M. Sondel (2016) "Immunocytokines for cancer treatment: past, present and future". *Curr. Opin. Immunol.*, 40, 96-102.

316 – G. Acker, A. Palumbo, **D. Neri**, P. Vajkoczy, M. Czabanka (2016) "F8-SIP mediated targeted photodynamic therapy leads to microvascular dysfunction and reduced glioma growth". *J. Neurooncol.*, 129, 33-38.

317 – Y. Li, E. Gabriele, F. Samain, N. Favalli, F. Sladojevich, J. Scheuermann, **D. Neri** (2016) "Optimized reaction conditions for amide bond formation in DNA-encoded combinatorial libraries". *ACS Comb. Sci.*, 18, 438-443.

318 – D. Venetz, D. Koovely, B. Weder, **D. Neri** (2016) "Targeted reconstitution of cytokine activity upon antigen binding using split cytokine antibody fusion proteins". *J. Biol. Chem.*, 291, 18139-18147.

319 – G. Zimmermann, **D. Neri** (2016) "DNA-encoded chemical libraries: foundations and applications in lead discovery". *Drug Discov. Today*, 21, 1828-1834.

320 – F. Bootz, B. Ziffels, **D. Neri** (2016) "Antibody-based targeted delivery of interleukin-22 promotes rapid clinical recovery in mice with DSS-induced colitis". *Inflamm. Bowel. Dis.*, 22, 2098-2105.

321 – F. Bootz, D. Venetz, B. Ziffels, **D. Neri** (2016) "Different tissue distribution properties forglycosylation variants of fusion proteins containing the p40 subunit of murine interleukin-12". *Protein Eng. Des. Sel.*, 29, 445-455.

322 – S. Cazzamalli, A. Dal Corso, **D. Neri** (2016) "Acetazolamide serves as selective delivery vehicle for dipeptide-linked drugs to renal cell carcinoma". *Mol. Cancer Ther.*, 15, 2926-2935.

323 – B. Ziffels, J. Ospel, K. Grün, **D. Neri**, A. Pfeil, M. Fritzenwanger, H.R. Figulla, C. Jung, A. Berndt, M. Franz (2016) "Detection of soluble ED-A(+) fibronectin and evaluation as novel serum biomarker for cardiac tissue remodeling". *Dis. Markers*, 2016:3695454.

324 – A. Gloger, D. Ritz, T. Fugmann, **D. Neri** (2016) "Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes". *Cancer Immunol. Immunother.*, 65, 1377-1393.

325 – A. Roos, U. Pradere, R.P. Ngondo, A. Behera, S. Allerini, G. Civenni, J.A. Zagalak, J.R. Marchand, M. Menzi, H. Towbin, J. Scheuermann, **D. Neri**, A. Caflisch, C.V. Catapano, C. Ciaudo, J. Hall. "A small-molecule inhibitor of Lin28". *ACS Chem. Biol.*, 11, 2773-2781.

326 – M. Franz, K. Grün, S. Betge, I. Rohm, B. Ngongson-Dongmo, R. Bauer, P.C. Schulze, M. Lichtenauer, I. Petersen, **D. Neri**, A. Berndt, C. Jung. "Lung tissue remodeling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression". *Oncotarget*, 7, 81241-81254.

327 – D. Ritz, A. Gloger, **D. Neri**, T Fugmann (2017) "Purification of soluble HLA class I complexes from human serum or plasma delivers high quality immune-peptidomes required for biomarker discovery". *Proteomics*, 10.1002/pmic.201600364.

328 – S. Cazzamalli, A. Dal Corso, **D. Neri** (2017) "Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma". *J. Control. Release*, 246, 39-45.

329 – R. Gébleux, M. Stringhini, R. Casanova, A. Soltermann, **D. Neri** (2017) "Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.". *Int. J. Cancer*, 140, 1670-1679.

330 – T. Fugmann, A. Sofron, D. Ritz, F. Bootz, **D. Neri** (2017) "The MHC class II immunopeptidome of lymph nodes in health and in chemically-induced colitis". *J. Immunol.*, 198, 1357-1364.

331 – G. Zimmermann, Y. Li, U. Rieder, M. Mattarella, **D. Neri***, J. Scheuermann (2017) "Hit-validation methodologies for ligands isolated from DNA-encoded chemical libraries". *ChemBioChem*, 18, 853-857. [* = corresponding author].

332 – B. Weide, **D. Neri**, G. Elia (2017) "Intralesional treatment of metastatic melanoma: a review of therapeutic options". *Cancer Immunol. Immunother.*, 66, 647-656.

333 – Y. Li, G. Zimmermann, J. Scheuermann, **D. Neri** (2017) "Quantitative PCR is a valuable tool to monitor the performance of DNA-encoded chemical library selections". *ChemBioChem*, 18, 848-852.

334 – **D. Neri** (2017) "Twenty-five years of DNA-encoded chemical libraries". *ChemBioChem*, 18, 827-828.

335 – B. Robl, S.M. Botter, A. Boro, D. Meier, **D. Neri**, B. Fuchs (2017) "Evaluation of F8-TNFa in models of early and progressive osteosarcoma". *Transl. Oncol.*, 10, 419-430.

336 – P. Probst, J. Kopp, A. Oxenius, M.P. Colombo, D. Ritz, T Fugmann, **D. Neri** (2017) "Sarcoma eradication by doxorubicin and targeted TNF relies upon CD8+ T-cell recognition of a retroviral antigen". *Cancer Res.*, 77, 3644-3454.

337 – G. Zimmermann, U. Rieder, D. Bajic, S. Vanetti, A. Chaikuad, S. Knapp, J. Scheuermann, M. Mattarella, **D. Neri** (2017) "A specific and covalent JNK-1 ligand selected from an encoded self-assembling chemical library". *Chemistry*, 23, 8152-8155.

338 – A. Dal Corso, S. Cazzamalli, R. Gébleux, M. Mattarella, **D. Neri** (2017) "Protease-cleavable linkers modulate the anticancer activity of non-internalizing antibody-drug conjugates". *Bioconj. Chem.*, 28, 1826-1833.

339 – L. Angenendt, S. Reuter, D. Kentrup, A.S. Benk, F. Neumann, J. Hüve, A.C. Martens, C. Schwöppe, T. Kessler, L.H.Schmidt, T. Sauer, C. Brand, J.H. Mikesch, G. Lenz, R.M. Mesters, C. Müller-Tidow, W. Hartmann, E. Wardelmann, **D. Neri**, W.E. Berdel, C. Roesli, C. Schliemann (2017) "An atlas of blood-stream accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia". *Leukemia*, 32, 510-519.

340 – R. De Luca, A. Soltermann, F. Pretto, C. Pemberton-Ross, G. Pellegrini, S. Wulhfard, **D. Neri** (2017) "Potency-matched dual-cytokine antibody fusion proteins for cancer therapy". *Mol. Cancer Ther.*, 16, 2442-2451.

341 – D. Ritz, J. Kinzi, **D. Neri***, T. Fugmann (2017) "Data-independent acquisition of HLA class I peptidomes on the Q Exactive mass spectrometer platform". *Proteomics*, doi: 10.1002/pmic.201700177. [*) Corresponding author].

342 - A. Dal Corso, R. Gébleux, P. Murer, A. Soltermann, **D. Neri** (2017) "A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo". *J. Control. Rel.*, 264, 211-218.

343 – M. Bigatti, A. Dal Corso, S. Vanetti, S. Cazzamalli, U. Rieder, J. Scheuermann, **D. Neri***, F. Sladojevich (2017) "Impact of a Central Scaffold on the Binding Affinity of Fragment Pairs Isolated from DNA-Encoded Self-Assembling Chemical Libraries" *ChemMedChem*, 12, 1748-1752 [*) Corresponding author].

344 – S. Cazzamalli, A. Dal Corso, **D. Neri** (2017) "Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments". *Chimia*, 71 712-715.

345 – Y. Li, R. De Luca, S. Cazzamalli, F. Pretto, D. Bajic, J. Scheuermann, **D. Neri** (2018) "Versatile protein recognition by the encoded display of multiple chemical elements on a constant macrocyclic scaffold". *Nature Chem.*, 10, 441-448.

346 – **D. Neri**, R.A. Lerner (2018) "DNA-encoded chemical libraries: a selection system based on endowing chemical compounds with amplifiable information". *Annu. Rev. Biochem.*, 87, 479-502

347 – D. Ritz, E. Sani, H. Debiec, P. Ronco, **D. Neri**, T. Fugmann (2018) "Membranal and soluble HLA class II peptidome analyses using data-dependent and independent acquisition". *Proteomics*, doi: 10.1002/pmic.201700246.

348 – H.D. Menssen, U. Harnack, U. Erben, **D. Neri**, B. Hirsch, H. Dürkop (2018) "Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model". *J. Cancer Res. Clin. Oncol.*, 144, 499-507.

349 – S. Cazzamalli, A. Dal Corso, F. Widmayer, **D. Neri** (2018) "Chemically-defined antibody- and small molecule-drug conjugates for *in vivo* tumor targeting applications: a comparative evaluation". *J. Am. Chem. Soc.*, 140, 1617-1621.

350 – A. Schmid, T. Hemmerle, F. Pretto, A. Kipar, **D. Neri** (2018) "Antibody-based targeted delivery of interleukin-4 synergizes with dexamethasone for the reduction of inflammation in arthritis". *Rheumatology*, 57, 748-755.

351 – B. Ziffels, F. Pretto, **D. Neri** (2018) "Intratumoral administration of IL2 and TNF-based fusion proteins cures cancer without establishing protective immunity". *Immunotherapy*, 10, 177-188.

352 – A. Schmid, D. Tintor, **D. Neri** (2018) "Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads". *J. Biotechnol.*, 271, 29-36.

353 – N.H. Rekers, V. Olivo Pimentel, A. Yaromina, N.G. Lieuwes, R. Biemans, C.M.L. Zegers, W.T. V. Germeraad, E.J. Van Limbergen, **D. Neri**, L.J. Dubois, P. Lambin (2018) "The immunocytokine L19-IL2: an interplay between radiotherapy and long-lasting systemic anti-tumor immune responses". *Oncoimmunology*, e1414119

354 – N. Favalli, G. Bassi, J. Scheuermann, **D. Neri** (2018) "DNA-encoded chemical libraries: achievements and remaining challenges". *FEBS Lett.*, 592, 2168-2180.

355 – S. Cazzamalli, B. Ziffels, F. Widmayer, P. Murer, G. Pellegrini, F. Pretto, S. Wulhfard, **D. Neri** (2018) "Enhanced therapeutic activity of non-internalizing small-molecule-drug conjugates targeting carbonic anhydrase IX in combination with targeted interleukin-2". *Clin. Cancer Res.*, 24, 3656-3667.

356 – N. Savic, F.C. Ringnalda, H. Lindsay, C. Berk, K. Bargsten, Y. Li, **D. Neri**, M.D. Robinson, C. Ciaudo, J. Hall, M. Jinek, G. Schwank G. (2018) "Covalent linkage of the DNA repair template to the CRISPR-Cas9 nuclease enhances homology-directed repair". *Elife*, e33761

357 – N. Favalli, S. Biendl, M. Hartmann, J. Piazzi, F. Sladojevich, S. Gräslund, P.J. Brown, K. Näreoja, H. Schüler, J. Scheuermann, R. Franzini, **D. Neri** (2018). "A DNA-encoded library of chemical compounds based on common scaffolding structures reveals the impact of ligand geometry on protein recognition". *ChemMedChem*, 13, 1303-1307.

358 – G. Acker, S.K. Piper, A.L. Datwyler, T. Broggini, I. Kremenetskaia, M. Nieminen-Kelhä, J. Lips, U. Harms, S. Mueller, G. Lättig-Tünnemann, E. Trachsel, A. Palumbo, **D. Neri**, J. Klohs, M. Endres, P. Vajkoczy, C. Harms, M. Czabanka (2018) "Targeting the extra-domain A of fibronectin allows identification of vascular resistance to antiangiogenic therapy in experimental glioma". *Oncotarget*, 9, 27760-27772.

359 – R. De Luca, **D. Neri** (2018) "Potentiation of PD-L1 blockade with a potency-matched dual-cytokine antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains". *Cancer Immunol. Immunother.*, 67, 1381-1391.

360 – R. De Luca, P. Kachel, K. Kropivsek, B. Snijder, M. Manz, **D. Neri** (2018) "A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignancies. *Protein Engin. Des. Sel.*, 31, 173-179.

361 – A. Del Corso, M. Catalano, A. Schmid, J. Scheuermann, **D. Neri** (2018) "Affinity enhancement of protein ligands by reversible covalent modification of neighboring lysine residues". *Angew. Chem. Int. Ed. Engl.*, 57, 17178-17182.

362 - C. Hutmacher, **D. Neri** (2018) "Antibody-cytokine fusion proteins: biopharmaceuticals with immunomodulatory properties for cancer therapy". *Adv. Drug Deliv. Rev.*, 141, 67-91.

363 – S. Cazzamalli, E. Figueras, L. Pethő, A. Borbély, C. Steinkühler, **D. Neri**, N. Sewald (2018) "In vivo antitumor activity of a novel acetazolamide-cryptophycin conjugate for the treatment of renal cell carcinomas". *ACS Omega*, 3, 14726-14731.

364 – P. Probst, M. Stringhini, D. Ritz, T. Fugmann, **D. Neri** (2019) "Antibody-based delivery of TNF to the tumor neo-vasculature potentiates the therapeutic activity of a peptide anti-cancer vaccine". *Clin. Cancer Res.*, 25, 698-709.

365 – P. Murer, J.D. Kiefer, L. Plüss, M. Matasci, S. Bluemich, **D. Neri** (2019) "Targeted delivery of TNF potentiates the antibody-dependent cell-mediated cytotoxicity of an anti-melanoma immunoglobulin". *J. Invest. Dermatol.*, 139, 1339-1348.

366 – S. Schwager, S. Renner, T. Hemmerle, S. Karaman, S.T. Proulx, R. Fetz, A.M. Golding-Ochsenbein, P. Probst, C. Halin, **D. Neri**, M. Detmar (2019) "Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation". *JCI Insight*, 3: pii: 124850.

367 – A. Sannino, E. Gabriele, M. Bigatti, S. Mulatto, J. Piazzi, J. Scheuermann, **D. Neri**, E.J. Donckele, F. Samain (2019) "Quantitative assessment of affinity selection performance by using DNA-encoded chemical libraries". *Chembiochem*, 20, 955-962.

368 – S.T.G. Bruijnen, D.M.S.H. Chandrupatla, L. Giovanonni, **D. Neri**, D.J. Vugts, M.C. Huisman, O.S. Hoekstra, R.J.P. Musters, A.A. Lammertsma, G.A. van Dongen, G. Jansen, C.F.M. Molthoff, C.J. van der Laken (2019) "F8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET-Guided Translational Approach.". *Mol. Pharm*., 16, 273-281.

369 – B. Ziffels, A. Grötsch, L. Al-Bayati, **D. Neri** (2019) "Targeted delivery of calreticulin to ED-A fibronectin leads to tumor-growth retardation." *J. Biotechnol.*, 290, 53-58.

370 – T. Ongaro, M. Matasci, S. Cazzamalli, B. Gouyou, R. De Luca, **D. Neri**, A. Villa (2019) "A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors". *J. Biotechnol*., 291, 17-25.

371 – C. Hutmacher, N. Núñez, A.R. Liuzzi, B. Becher, **D. Neri** (2019) "Targeted delivery of IL2 to the tumor stroma potentiates the action of immune checkpoint inhibitors by preferential activation of NK cells and CD8+ T cells". *Cancer Immunol. Res*., 7, 572-583.

372 – A.S. Schmid, **D. Neri** (2019) "Advances in antibody engineering for rheumatic diseases". *Nat. Rev. Rheumatol*., 15, 197-207.

373 – **D. Neri** (2019) "Antibody-cytokine fusions: versatile products for the modulation of anticancer immunity". *Cancer Immunol. Res*., 7, 348-354.

374 – P. Akkapeddi, R. Fragoso, J.A. Hixon, A.S. Ramalho, M.L. Oliveira, T. Carvalho, A. Gloger, M. Matasci, F. Corzana, S.K. Durum, **D. Neri**, G.J.L. Bernardes, J.T. Barata (2019) " A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia". *Leukemia*, 33, 2155-2168.

375 – L.H. Yuen, S. Dana, Y. Liu, S.I. Bloom, A.G. Thorsell, **D. Neri**, A.J. Donato, D.B. Kireev, H. Schüler, R.M. Franzini (2019) "A Focused DNA-Encoded Chemical Library for the Discovery of Inhibitors of NAD_+-Dependent Enzymes." *J. Am. Chem. Soc*., 141, 5169-5181.

376 – P. Murer, **D. Neri** (2019) "Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation." *N. Biotechnol*, 52, 42-53.

377 – A.H. Willrodt, A.C. Salabarria, P. Schineis, D. Ignatova, M.C. Hunter, M. Vranova, A.M. Golding-Ochsenbein, E. Sigmund, A. Romagna, V. Strassberger, M. Fabbi, S. Ferrini, C. Cursiefen, **D. Neri**, E. Guenova, F. Bock, C. Halin (2019) "ALCAM Mediates DC Migration

Through Afferent Lymphatics and Promotes Allospecific Immune Reactions." *Front. Immunol.*, 10, 759.

378 – B. Ziffels, M. Stringhini, P. Probst, T. Fugmann, T. Sturm, **D. Neri** (2019) "Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice." *Mol. Cancer Ther.,* 18, 1544-1554.

379 – C. Hutmacher, L. Volta, F. Rinaldi, P. Murer, R. Myburgh, M.G. Manz, **D. Neri** "Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.". *Leukemia Res.*, 84, 106178.

380 – A.S. Schmid, **D. Neri** (2019) "Design and characterisation of a novel interleukin-15 receptor alpha fusion protein and analysis of interleukin-15 complexation.". *PLoS One,* 14, e0219313.

381 – B. Weide, T. Eigentler, C. Catania, P.A. Ascierto, S. Cascinu, J.C. Becker, A. Hauschild, A. Romanini, R. Danielli, R. Dummer, U. Trefzer, G. Elia, **D. Neri**, C. Garbe (2019) "A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.". *Cancer Immunol. Immunother.*, 68, 1547-1559.

382 – S. Ghiasikhou, S. Cazzamalli, J. Scheuermann, **D. Neri**, R. Zenobi (2019) "Automated and enhanced extraction of a small molecule-drug conjugate using an enzyme-inhibitor interaction based SPME tool followed by direct analysis by ESI-MS.". *Anal. Bioanal. Chem.*, 411, 7387-7398.

383 – A. Gironda-Martínez, **D. Neri**, F. Samain, E.J. Donckele (2019). "DNA-Compatible Diazo-Transfer Reaction in Aqueous Media Suitable for DNA-Encoded Chemical Library Synthesis.". *Org. Lett.*, 21, 9555-9558.

384 – E. Puca, P. Probst, M. Stringhini, P. Murer, G. Pellegrini, S. Cazzamalli, C. Hutmacher, B. Gouyou, S. Wulhfard, M. Matasci, A. Villa, **D. Neri** (2020) "The antibody-based delivery of interleukin-12 to solid tumors boosts NK and $CD8_+$ T cell activity and synergizes with immune checkpoint inhibitors.". *Int. J. Cancer*, 146, 2518-2530.

385 – E. Puca, R. De Luca, F. Seehusen, J.M.M. Rodriguez, **D. Neri** (2020). "Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice". *J. Control. Release*, 317, 282-290.

386 – R. De Luca, B. Gouyou, T. Ongaro, A. Villa, B. Ziffels, A. Sannino, G. Buttinoni, S. Galeazzi, M. Mazzacuva, **D. Neri** (2020) "A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas". *Front. Oncol.*, 9, 1228. doi: 10.3389/fonc.2019.01228

387 – S. Dakhel, T. Ongaro, B. Gouyou, M. Matasci, A. Villa, **D. Neri**, S. Cazzamalli (2020) "Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade" *Oncotarget*, 10, 6678-6690.

388 – P. Murer, L. Plüss, **D. Neri** (2020) "A novel human monoclonal antibody specific tot he A33 glycoprotein recognizes colorectal cancer and inhibits metastasis" *MAbs*, 12, 1714371. doi: 10.1080/19420862.2020.1714371.

389 – N.J. Kräutler, A. Yermanos, A. Pedrioli, S.P.M. Welten, D. Lorgé, U. Greczmiel, I. Bartsch, J. Scheuermann, J.D. Kiefer, K. Eyer, U. Menzel, V. Greiff, **D. Neri**, T. Stadler, S.T. Reddy, A. Oxenius (2020) "Quantitative and qualitative analysis of humoral immunity reveals continued and personalized evolution in chronic viral infection". *Cell Rep.*, 30, 997-1012.

390 – J. Mock, C. Pellegrino, **D. Neri** (2020) "A universal reporter cell line for bioactivity evaluation of engineered cytokine products". *Sci. Rep.,* 10, 3234. doi: 10.1038/s41598-020-60182-4.

391 – L. Prati, M. Bigatti, E.J. Donckele, **D. Neri**, F. Samain (2020) "On-DNA hit validation methodologies for ligands identified from DNA-encoded chemical libraries". *Biochem. Biophys. Res. Commun.,* 533, 235-240.

392 – R. Myburgh, J.D. Kiefer, N.F. Russkamp, C.F. Magnani, N. Nuñez, A. Simonis, S. Pfister, C.M. Wilk, D. McHugh, J. Friemel, A.M. Müller, B. Becher, C. Münz, M. van den Broek, **D. Neri**, M.G. Manz (2020) "Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells ". *Leukemia*, 34, 2688-2703.

393 – G. Bassi, N. Favalli, S. Oehler, A. Martinelli, M. Catalano, J. Scheuermann, **D. Neri** (2020) "Comparative evaluation of DNA-encoded chemical selections performed using DNA in single-stranded or double-stranded format". *Biochem. Biophys. Res. Commun.,* 533, 223-229.

394 – A. Sannino, A. Gironda-Martínez, E.M.D. Gorre, L. Prati, J. Piazzi, J. Scheuermann, **D. Neri**, E.J. Donckele, F. Samain (2020). "Critical evaluation of photo-cross-linking parameters for the implementation of efficient DNA-encoded chemical library selections". *ACS Comb. Sci.*, 22, 204-212.

395 – R. Corbellari, L. Nadal, A. Villa, **D. Neri**, R. De Luca (2020). "The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors". *Anticancer Drugs*, 31, 799-805.

396 – **D. Neri**, R.A. Lerner (2020). "Reflections on DNA-encoded chemical libraries". *Biochem. Biophys. Res. Commun.,* 527, 757-759.

397 – M. Stringhini, P. Probst, **D. Neri** (2020). "Immunotherapy of CT26 murine tumors is characterized by an oligoclonal response of tissue-resident memory T cells against the AH1 rejection antigen". *Eur. J. Cancer*, 50, 1591-1597.

398 – C. Pellegrino, N. Favalli, M. Sandholzer, L. Volta, G. Bassi, J. Millul, S. Cazzamalli, M. Matasci, A. Villa, R. Myburgh, M.G. Manz, **D. Neri** (2020). "Impact of ligand size and conjugation chemistry on the performance of universal chimeric antigen receptor T-cells for tumor killing". *Bioconj. Chem.*, 31, 1775-1783.

399 – M. Catalano, S. Oehler, L. Prati, N. Favalli, G. Bassi, J. Scheuermann, **D. Neri** (2020). "Complexation with a cognate antibody fragment facilitates affinity measurements of fluorescein-linked small molecule ligands". *Anal. Chem.*, 92, 10822-10829.

400 – R.I.Y. Lieverse, E.J. Van Limbergen, C.J.G. Oberije, E.G.C. Troost, S.R. Hadrup, A.C. Dingemans, L.E.L. Hendriks, F. Eckert, C. Hiley, C. Dooms, Y. Lievens, M.C. de Jong, J. Bussink, X. Geets, V. Valentini, G. Elia, **D. Neri**, C. Billiet, A. Abdollahi, D. Pasquier, P. Boisselier, A. Yaromina, D. De Ruysscher, L.J. Dubois, P. Lambin (2020). "Stereotactive ablative radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in Stage IV NSCLC patients, IMMUNOSABR: a multicenter, randomized controlled open-label Phase II trial". *BMC Cancer*, 20, 557. doi: 10.1186/s12885-020-07055-1.

401 – T. Weiss, E. Puca, M. Silginer, S. Pazahr, A. Bink, T Hemmerle, M. Weller, **D. Neri***, P. Roth (2020). "Immunocytokines are a novel immunotherapeutic approach against glioblastoma". *Sci. Transl. Med.*, 12(564): eabb2311 [*) Corresponding Author].

402 – J. Scheuermann, **D. Neri** (2020). "Special edition on DNA-encoded chemical libraries". *Biochem. Biophys. Res. Commun.,* 533(2):iii-iv.

403 – F. Walser , M.P.C. Mulder, B. Bragantini, S. Burger, T. Gubser, M. Gatti, M.V. Botuyan, A. Villa, M. Altmeyer, **D. Neri**, H. Ovaa, G. Mer, L. Penengo (2020) "Ubiquitin phosphorylation at Thr12 modulates the DNA damage response ". *Mol. Cell*, 80, 423-426.

404 – J. Mock, M. Stringhini, M. Weller, T. Weiss, **D. Neri** (2020) "An engineered 4-1BBL fusion protein with activity on demand". *Proc. Natl. Acad. Sci. U.S.A.*, 117, 31780-31788.

405 – B. Gouyou, J. Millul, A. Villa, S. Cazzamalli, **D. Neri**, M. Matasci (2020) "Sortase-mediated site-specific modification of interleukin-2 for the generation of tumor-targeting acetazolamide-cytokine conjugates". *ACS Omega*, 5, 26077-26083.

406 – M. Catalano, M. Moroglu, P. Balbi, F. Mazzieri, J. Clayton, K.H. Andrews, M. Bigatti, J. Scheuermann, S.J. Conway, **D. Neri** (2020) "Selective fragments for CREBBP bromodomain identified from an encoded self-assembly chemical library". *ChemMedChem*, 15, 1752-1756.

407 – M.R. Mortensen, J. Mock, M Bertolini, M. Stringhini, M. Catalano, **D. Neri** (2020) "Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors". *Oncotarget*, 11, 3972- 3983.

408 – T. Ongaro, B. Gouyou, M. Stringhini, R. Corbellari, **D. Neri**, A. Villa (2020) "A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor targeting properties *in vivo*". *Oncotarget*, 11, 3698-3711.

409 – L. Nadal, R. Corbellari, A. Villa, T. Weiss, M. Weller, **D. Neri**, R. De Luca (2020) "Novel human monoclonal antibodies specific to the alternatively spliced domain D of tenascin-C efficiently target tumors *in vivo*". *MAbs*, 12, 1836713. doi: 10.1080/19420862.2020.1836713.

410 – D. Bajic, K. Chester, **D. Neri** (2020). "An antibody-tumor necrosis factor fusion protein that synergizes with oxaliplatin for treatment of colorectal cancer". *Mol. Cancer Ther.*, 19, 2554-2563.

411 – G. Bassi, N. Favalli, M. Vuk, M. Catalano, A. Martinelli, A. Trenner, A. Porro, S. Yang, C.L. Tham, M. Moroglu, W.W. Yue, S.J. Conway, P.K. Vogt, A.A. Sartori, J. Scheuermann, **D. Neri** (2020). "A single-stranded DNA-encoded chemical library based on a stereoisomeric scaffold enables ligand discovery by modular assembly of building blocks". *Adv. Sci.*, 7, 2001970 doi: 10.1002/advs.202001970.

412 – E. Puca, C. Schmitt-Koopmann, M. Furter, P. Murer, P. Probst, M. Dihr, D. Bajic, **D. Neri** (2020). "The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and $CD8^+$ T cell in an immunocompetent mouse model of colorectal cancer". *J. Gastrointest. Oncol.*, 11, 803-811.

413 – O.C. Kulterer, S. Pfaff, W. Wadsak, N. Garstka, M. Remzi, C. Vraka, L. Nics, F. Bootz, S. Cazzamalli, N. Krall, **D. Neri**, A.R. Haug (2021). "A microdosing study with ^{99m}Tc-PHC-102 for the SPECT/CT imaging of primary and metastatic lesions in renal cell carcinoma patients". *J. Nucl. Med.*, 62, 360-365.

414 – J. Millul, C. Krudewig, A. Zana, S. Dakhel Plaza , E. Puca, A. Villa, **D. Neri***, S. Cazzamalli (2021) "Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX". *Mol. Cancer Ther.*, 20, 512-522 [*) Corresponding Author].

415 – N.F. Russkampf, R. Myburgh, J.D. Kiefer, **D. Neri**, M.G. Manz (2021) "Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells". *Exp. Hematol.*, 95, 31-45.

416 – B. Gouyou, T. Ongaro, S. Cazzamalli, R. De Luca, A. Kerschenmeyer, P. Valet, A. Villa, **D. Neri**, M. Matasci (2021) "Antibody-based delivery of interleukin-9 to neovascular structures: therapeutic evaluation in cancer and in arthritis". *Exp. Biol. Med.*, 246, 940-951.

417 – M. Stringhini, J. Mock. V. Fontana, P.Murer, **D. Neri** (2021). "Antibody-mediated delivery of LiGHT to the tumor boosts natural killer cells and delays tumor progression". *MAbs*, 13, 1868066.

418 – Y. Onda, G. Bassi, A. Elsayed, F. Ulrich, S. Oehler, L. Plais, J. Scheuermann, **D. Neri**. (2021) "A DNA-encoded library based on peptide macrocycles". *Chemistry*, 27, 7160-7167.

419 – R. Corbellari, M. Stringhini, J. Mock, T. Ongaro, A. Villa, **D. Neri***, R. De Luca (2021) "A novel antibody-IL15 fusion protein selectively localizes to tumors, synergizes with TNF-based immunocytokine, and inhibits metastasis. *Mol. Cancer Ther.*, 20, 859-871. [*) Corresponding Author].

420 – V. Olivo Pimentel, D. Marcus, A.M. van der Wiel, N.G. Lieuwes, R. Biemans, R.I. Lieverse, **D. Neri**, J. Theys, A. Yaromina, L.J. Dubois, P. Lambin. (2021) "Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.". *J. Immunother. Cancer*, 9, e001764.

421 – B. Gouyou, K. Grün, A. Kerschenmeyer, A. Villa, M. Matasci, A. Schrepper, A. Pfeil, L. Bäz, C. Jung, P.C. Schulze, **D. Neri**, M. Franz. (2021) "Therapeutic Evaluation of Antibody-

Based Targeted Delivery of Interleukin 9 in Experimental Pulmonary Hypertension.". *Int. J. Mol.. Sci.*, 22, 3460.

422 – T. Ongaro, S.R. Guarino, L. Scietti, M. Palamini, S. Wulhfard, **D. Neri**, A. Villa, F. Forneris F. (2021) "Inference of molecular structure for characterization and improvement of clinical grade immunocytokines.". *J. Struct. Biol.*, 213, 107696.

423 – J. Millul, G. Bassi, J. Mock, A. Elsayed, C. Pellegrino, A. Zana, S. Dakhel Plaza, L. Nadal, A. Gloger, E. Schmidt, I. Biancofiore, E.J. Donckele, F. Samain, **D. Neri***, S. Cazzamalli. (2021). "An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications.". *Proc. Natl. Acad. Sci. U.S.A.,* 118, e2101852118. [*) Corresponding Author].

424 – M. Stringhini, I. Spadafora, M. Catalano, J. Mock, P. Probst, R. Spörri, **D. Neri** (2021). "Cancer therapy in mice using a pure population of $CD8^+$ T cell specific to the AH1 tumor rejection antigen.". *Cancer Immunol. Immunother.*, 70, 3183-3197.

425 – E. Rosini, N.A. Volpi, B. Ziffels, A. Grimaldi, S. Sacchi, **D. Neri**, L. Pollegioni. (2021) "An antibody-based enzymatic therapy for cancer treatment: The selective localization of D-amino acid oxidase to EDA fibronectin". *Nanomedicine*, 36, 102424.

426 – N. Favalli, G. Bassi, C. Pellegrino, J. Millul, R. De Luca, S. Cazzamalli, S. Yang, A. Trenner, N.L. Mozaffari, R. Myburgh, M. Moroglu, S.J. Conway, A.A. Sartori, M.G. Manz, R.A. Lerner, P.K. Vogt, J. Scheuermann, **D. Neri**. (2021) "Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications.". *Nat. Chem.*, 13, 540-548.

427 – C. Schliemann, T. Hemmerle, A.F. Berdel, L. Angenendt, A. Kerkhoff, J.P. Hering, W. Heindel, W. Hartmann, E. Wardelmann, S.P. Chawla, F. de Braud, G. Lenz, **D. Neri**, T. Kessler, W.E. Berdel. (2021). "Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.". *Eur. J. Cancer*, 150, 143-154.

428 – S. Oehler, M. Catalano, I. Scapozza, M. Bigatti, G. Bassi, N. Favalli, M.R. Mortensen, F. Samain, J. Scheuermann, **D. Neri**. (2021) "Affinity Selections of DNA-Encoded Chemical Libraries on Carbonic Anhydrase IX-Expressing Tumor Cells Reveal a Dependence on Ligand Valence.". *Chemistry*, 27, 8985-8993.

429 – N. Favalli, G. Bassi, D. Bianchi, J. Scheuermann, **D. Neri** (2021) "Large screening of DNA-compatible reaction conditions for Suzuki and Sonogashira cross-coupling reactions and for reverse amide bond formation.". *Bioorg. Med. Chem.*, 41, 116202.

430 – C. Schliemann, T. Kessler, A.F. Berdel, T. Hemmerle, L. Angenendt, B. Altvater, C. Rossig, J.H. Mikesch, G. Lenz, M. Schäfers, **D. Neri**, M. Stelljes, W.E. Berdel. (2021) "Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation." *Br. J. Haematol.*, 192, e148-e151.

431 – A. Gironda-Martínez, E.J. Donckele, F. Samain, **D. Neri** (2021) "DNA-encoded chemical libraries: a comprehensive review with successful stories and future challenges". *ACS Pharmacol. Transl. Sci.*, 4, 1265-1279

432 – S. Oehler, L. Plais, G. Bassi, **D. Neri***, J. Scheuermann (2021) "Modular assembly and encoding strategies for dual-display DNA-encoded chemical libraries". *Chem. Commun.*, 57, 12289-12292 [*) Corresponding Author].

433 – S. Dakhel, C. Lizak, M. Matasci, J. Mock, A. Villa, **D. Neri***, S. Cazzamalli (2021) "An attenuated targeted-TNF localizes to tumors *in vivo* and regains activity at the site of disease". *Int. J. Mol. Sci.*, 122, 10020 [*) Corresponding Author].

434 – G. Bassi, N. Favalli, C. Pellegrino, Y. Onda, J. Scheuermann, S. Cazzamalli, M.G. Manz, **D. Neri** (2021) "Specific inhibitor of placental alkaline phosphatase isolated from a DNA-encoded chemical library targets tumor of the female reproductive tract". *J. Med. Chem.*, 64, 15799-15809

435 – P. Backhaus, F. Gierse, M.C. Burg, F. Büther, I. Asmus, P. Dorten, J. Cufe, W. Roll, **D. Neri**, S. Cazzamalli, J. Millul, J. Mock, A. Galbiati, A. Zana, K.P. Schäfers, S. Hermann, M. Weckesser, J. Tio, S. Wagner, H.J. Breyholz, M. Schäfers (2022). "Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA". *Eur. J. Nucl. Med. Mol. Imaging*, 49, 1822-1832.

436 – L. Plais, A. Lessing, M. Keller, A. Martinelli, S. Oehler, G. Bassi, **D. Neri**, J. Scheuermann (2022). "Universal encoding of next generation DNA-encoded chemical libraries". *Chem. Sci.*, 13, 967-974.

437 – N. Bäumer, J. Tiemann, A. Scheller, T. Meyer, L. Wittmann, M.E.G. Suburu, L. Greune, M. Peipp, N. Kellmann, A. Gumnior, C. Brand, W. Hartmann, C. Rossig, C. Müller-Tidow, **D. Neri**, C.A. Strassert, C. Rüter, P. Dersch, G. Lenz, H.P. Koeffler, W.E. Berdel, S. Bäumer (2022). "Targeted siRNA nanocarrier: a platform technology for cancer treatment". *Oncogene*, 41, 2210-2224.

438 – C. Di Nitto, **D. Neri**, T. Weiss, M. Weller, R. De Luca (2022). "Design and characterization of novel antibody-cytokine fusion proteins based on interleukin-21". *Antibodies*, 11, 19.

439 – A.F. Berdel, L. Ruhnke, L. Angenendt, M. Wermke, C. Röllig, J.H. Mikesch, A. Scheller, T. Hemmerle, M. Matasci, K. Wethmar, T. Kessler, M. Gerwing, D. Hescheler, M. Schäfers, W. Hartmann, B. Altvater, C. Rossig, M. Bornhäuser, G. Lenz, M. Stelljes, B. Rueter, **D. Neri**, W.E. Berdel, C. Schliemann (2022). "Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI836858 for posttransplant AML relapse". *Blood Adv.*, 6, 3684-3696.

440 – A. Galbiati, A. Zana, M. Bocci, J. Millul, A. Elsayed, J. Mock, **D. Neri***, S. Cazzamalli (2022). "A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake". *J. Nucl. Med.*, 63, 1852-1858 [*) Corresponding Author].

441 – A. Zana, A. Galbiati, E. Gilardoni, M. Bocci, J. Millul, T. Sturm, R. Stucchi, A. Elsayed, L. Nadal, M. Cirillo, W. Roll, L. Stegger, I. Asmus, P. Backhaus, M. Schäfers, **D. Neri***, S. Cazzamalli (2022). "Fibroblast Activation Protein Triggers Release of Drug Payload from Non-internalizing Small Molecule Drug Conjugates in Solid Tumors.". *Clin. Cancer Res.*., 28, 5440-5454 [*) Corresponding Author].

442 – N. Cousin, S. Bartel, J. Scholl, C. Tacconi, A. Egger, G. Thorhallsdottir, **D. Neri**, L.C. Dieterich, M. Detmar (2022). "Antibody-Mediated Delivery of VEGF-C Promotes Long-Lasting Lymphatic Expansion That Reduces Recurrent Inflammation". *Cells*, 12, 172

443 – F. Peissert, L. Plüss, A.M. Giudice, T. Ongaro, A. Villa, A. Elsayed, L. Nadal, S. Dakhel Plaza, L. Scietti, E. Puca, R. De Luca, F. Forneris, **D. Neri** (2022). "Selection of a PD-1 blocking antibody from a novel fully human phage display library". *Protein Sci.*, 31, e4486

444 – L. Nadal, F. Peissert, A. Elsayed, T. Weiss, T. Look, M. Weller, G. Piro, C. Carbone, G. Tortora, M. Matasci, N. Favalli, R. Corbellari, C. Di Nitto, E. Prodi, C. Libbra, S. Galeazzi, C. Carotenuto, C. Halin, E. Puca, **D. Neri**, R. De Luca (2022). "Generation and *in vivo* validation of an IL12-fusion protein based on a novel anti-human FAP monoclonal antibody". *J. Immunother. Cancer.*, 10, e005282

445 – A.T. Hooper, K. Marquette, C.B. Chang, J. Golas, S. Jain, M.H. Lam, M. Guffroy, M. Leal, H. Falahatpisheh, D. Mathur, T. Chen, K. Kelleher, K. Khandke, E. Muszynska, F. Loganzo, E. Rosfjord, J. Lucas, Z. Kan, C. Subramanyam, C. O'Donnell, **D. Neri**, H.P. Gerber, C. May, P. Sapra (2022). "Anti-extra domain B splice variant of fibronectin antibody-drug conjugate eliminates tumor with enhanced activity when combined with checkpoint blockhade". *Mol. Cancer Ther.*, 21, 1462-1472

446 – N. Bäumer, A. Scheller, L. Wittmann, A. Faust, M. Apel, S.C. Nimmagadda, C. Geyer, K. Grunert, N. Kellmann, M. Peipp, S. Kailayangiri, M.E. Gutierrez Suburu, C.A. Strassert, M. Schenk, L. Greune, C. Rüter, P. Dersch, W. Hartmann, C. Rossig, **D. Neri**, C. Müller-Tidow, C. Schwöppe, C. Schliemann, G. Khandanpour, G. Lenz, W.E. Berdel, S. Bäumer (2022). "Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia". *J. Hematol. Oncol.*, 15, 171

447 – S. Dakhel, A. Galbiati, F. Migliorini, C. Comacchio, S. Oehler, L. Prati, J. Scheuermann, S. Cazzamalli, **D. Neri**, G. Bassi, N. Favalli (2022). "Isolation of a Natural Killer Group 2D small-molecule ligand from DNA-encoded chemical libraries". *ChemMedChem*, 17, e202200350

448 – E. Gilardoni, A. Zana, A. Galbiati, T. Sturm, J. Millul, S. Cazzamalli, **D. Neri**, R. Stucchi (2022). "A dimeric FAP-targeting small-molecule radioconjugate with high and prolonged tumor uptake". *Anal. Chem.*, 94, 10715-10721

449 – F. Bartoli, P. Elsinga, L.R. Nazario, A. Zana, A. Galbiati, J. Millul, F. Migliorini, S. Cazzamalli, **D. Neri**, R.H.J.A. Slart, P.A. Erba PA. (2022). "Automated radiosynthesis, preliminary in vitro/in vivo characterization of OncoFAP-based radiopharmaceuticals for cancer imaging and therapy". *Pharmaceutics*, 15, 958

450 – J. Heiss, K. Grün, L. Tempel, M. Matasci, A. Schrepper, M. Schwarzer, R. Bauer, M. Förster, A. Berndt, C. Jung, P.C. Schulze, **D. Neri**, M. Franz (2022). "Targeted interleukin-9 delivery in pulmonary hypertension: comparison of immunocytokine formats and effector cell study". *Eur. J. Clin. Invest.*, 53, e13907

451 – T. Look, E. Puca, M. Bühler, D. Kirschenbaum, R. De Luca, R. Stucchi, D. Ravazza, C. Di Nitto, P. Roth, Y. Katzenelenbogen, A. Weiner, L. Rindlisbacher, B. Becher, I. Amit, M. Weller, **D. Neri**, T. Hemmerle, T. Weiss (2023). "Targeted delivery of tumor necrosis factor in

combination with CCNU induces a T cell-dependent regression of glioblastoma". *Sci. Transl. Med.*, 15, eadf2281

452 – L.M. Brunner, Y. He, N. Cousin, J. Scholl, L.K. Albin, B. Schmucki, S. Supersaxo, G. Restivo, J. Hafner, **D. Neri**, S. Werner, M. Detmar (2023). "Promotion of lymphangiogenesis by targeted delivery of VEGF-C improves diabetic wound healing". *Cells*, 12, 472

453 – A. Zana, C. Puig-Moreno, M. Bocci, E. Gilardoni, C. Di Nitto, L. Principi, D. Ravazza, G. Rotta, E. Prodi, R. De Luca, **D. Neri**, S. Cazzamalli (2023). "A comparative analysis of fibroblast activation protein-targeted small molecule-drug, antibody-drug, and peptide-drug conjugates". *Bioconj. Chem.*, 34, 1205-1211

454 – C. Di Nitto, E. Gilardoni, J. Mock, L. Nadal, T. Weiss, M. Weller, F. Seehusen, C. Libbra, E. Puca, **D. Neri**, R. De Luca (2023). "An engineered IFNγ-antibody fusion protein with im,proved tumor-homing properties". *Pharmaceutics*, 15, 377

455 – A. Elsayed, C. Pellegrino, L. Plüss, F. Peissert, R. Benz, F. Ulrich, G. Thorhallsdottir, S.D. Plaza, A. Villa, J. Mock, E. Puca, R. De Luca, M.G. Manz, C. Halin, **D. Neri** (2023). "Generation of a novel fully-human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties". *MAbs*, 15, 2220839

456 – C.F. Magnani, R. Myburgh, S. Brunn, M. Chambovey, M. Ponzo, L. Volta, F. Manfredi, C. Pellegrino, S. Pascolo, C. Miskey, Z. Ivics, J.A. Shizuru, **D. Neri**, M.G. Manz (2023). "Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells". *Mol. Ther. Oncolytics*, 30, 56-71

457 – A.V. Stepanov, J. Xie, Q. Zhu, Z. Shen, W. Su, L. Kuai, R. Soll, C. Rader, G. Shaver, L. Douthit, D. Zhang, R. Kalinin, X. Fu, Y. Zhao, T. Qin, P.S. Baran, A.G. Gabibov, D. Bushnell, **D. Neri**, R.D. Kornberg, R.A. Lerner (2023). "Control of the anti-tumor activity and specificity of CAR T cells via organic adapters covalently tethering the CAR to tumour cells". *Nat Biomed. Eng.*, doi: 10.1038/s41551-023-01102-5

458 – A. Galbiati, P. Dorten, E. Gilardoni, F. Gierse, M. Bocci, A. Zana, J. Mock, M. Claesener, J. Cufe, F. Büther, K. Schäfers, S. Hermann, M. Schäfers, **D. Neri**, S. Cazzamalli, P. Backhaus (2023). "Tumor-targeted interleukin 2 boosts the anticancer activity of FAP-directed radioligand therapeutics". *J. Nucl. Med.*, 64, 1934-1940.

459 – Q. Zhou, X. Liu, **D. Neri**, W. Li, N. Favalli, G. Bassi, S. Yang, D. Yang, P.K. Vogt, M.W. Wang (2023). "Structural insights into the interaction of three Y-shaped ligands with PI3Kα". *Proc. Natl. Acad. Sci. U.S.A.*, 120, e2304071120.

460 – S. Puglioli, S. Oehler, L. Prati, J. Scheuermann, G. Bassi, S. Cazzamalli, **D. Neri***, N. Favalli (2023). "Impact of library input on the hit discovery rate in DNA-encoded chemical library selections". *Chem Sci.*, 14, 12026-12033 [*) Corresponding Author].

461 – S. Oehler, L. Lucaroni, F. Migliorini, A. Elsayed, L. Prati, S. Puglioli, M. Matasci, K. Schira, J. Scheuermann, D. Yudin, M. Jia, N. Ban, D. Bushnell, R. Kornberg, S. Cazzamalli, **D. Neri**, N. Favalli, G. Bassi (2023). "A DNA-encoded chemical library based on chiral 4-amino-proline enables stereospecific isozyme-selective protein recognition". *Nat. Chem.*, 15, 1431-1443.

462 – L. Bisbal Lopez, D. Ravazza, M. Bocci, A. Zana, L. Principi, S. Dakhel Plaza, A. Galbiati, E. Gilardoni, J. Scheuermann, **D. Neri**, L. Pignataro, C. Gennari, S. Cazzamalli, A. Dal Corso. (2023). "*Ex vivo*-mass spectrometry-based biodistribution analysis of an antibody-Resiquimod conjugate bearing a protease-cleavable and acid-labile linker". *Front. Pharmacol.*, 14, 1320524

463 – F. Peissert, M. Pedotti, R. Corbellari, L. Simonelli, R. De Gasparo, E. Tamagnini, L. Plüss, A. Elsayed, M. Matasci, R. De Luca, I. Cassaniti, J.C. Sammartino, A. Piralla, F. Baldanti, **D. Neri**, L. Varani (2023). "Adapting neutralizing antibodies to viral variants by structure-guided affinity maturation using phage display technology". *Glob. Chall.*, 7, 2300088

464 – J. Heiss, K. Grün, L. Tempel, M. Matasci, A. Schrepper, M. Schwarzer, R. Bauer, M. Förster, A. Berndt, C. Jung, P.C. Schulze, **D. Neri**, M. Franz (2023). "Targeted interleukin-9 delivery in pulmonary hypertension: comparison of immunocytokine formats and effector cell study". *Eur. J. Clin. Invest.*, 53, e13907

465 – E. Prodi, C. Comacchio, E. Gilardoni, C. Di Nitto, E. Puca, **D. Neri**, R. De Luca (2023). "An antibody targeting fibroblast activation protein simultaneously fused to interleukin-2 and tumor necrosis factor selectively localizes to neoplastic lesions". *Antibodies*, 12, 29

466 – L. Lucaroni, T. Georgiev, E. Prodi, S. Puglioli, C. Pellegrino, N. Favalli, L. Prati, M.G. Manz, S. Cazzamalli, **D. Neri**, S. Oehler, G. Bassi (2023). "Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics". *Eur. J. Nucl. Med. Mol. Imaging*, 50, 957-961

467 – W. Torng, I. Biancofiore, S. Oehler, J. Xu, J. Xu, I. Watson, B. Masina, L. Prati, N. Favalli, G. Bassi, **D. Neri**, S. Cazzamalli, J.A. Feng (2023). "Deep learning approach for the discovery of tumor-targeting small organic ligands from DNA-encoded chemical libraries". *ACS Omega*, 8, 25090-25100

468 – M. Bocci, A. Zana, L. Principi, L. Lucaroni, L. Prati, E. Gilardoni, **D. Neri**, S. Cazzamalli, A. Galbiati (2023). "In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment". *J. Control. Release.*, in press